What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2024-12-23 compared with 2023-11-27 · 1353 added, 1315 removed, 170 unchanged (94% of the section changed)

1 unchanged sentence

Anavex Life Sciences Corp.

is a clinical stage

biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous

system (“CNS”) diseases with high unmet need.

We analyze genomic data from clinical trials to identify biomarkers,

which we use in the analysis of our clinical trials.

Our lead product candidate, ANAVEX ® 2-73

(blarcamesine), is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central

nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by

mutations in the X-linked gene, methyl-CpG-binding protein 2 (“MECP2”).

We currently have two core programs and two

seed programs.

Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental

is a clinical stage biopharmaceutical

company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”)

diseases with high unmet need.

We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our

clinical trials.

Our focus is on developing innovative

treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,

including Rett syndrome, and other central nervous system (CNS) disorders.

We currently have two core programs and two seed programs.

Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.

The following table summarizes key information about our programs:

* = Orphan Drug Designation by the FDA

Ongoing trial

Anavex has a portfolio of compounds varying

in sigma-1 receptor (SIGMAR1) binding activities.

The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone

protein with important roles in cellular communication.

SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope

and restores homeostasis and stimulates recovery of cell function when activated.

In order to validate the ability of our compounds

to activate quantitatively the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission

Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX ® 2-73 (blarcamesine) target engagement

or receptor occupancy with SIGMAR1 in the brain.

Anavex has a portfolio of compounds varying in sigma-1

receptor (SIGMAR1) binding activities.

The SIGMAR1 gene encodes the SIGMAR1 protein, which is an intracellular chaperone protein with

important roles in cellular communication.

SIGMAR1 is also involved in transcriptional regulation at the nuclear envelope and restores

homeostasis and stimulates recovery of cell function when activated.

In order to validate the ability of our compounds to activate quantitatively

the SIGMAR1, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography (PET) imaging scan in

mice, which demonstrated a dose-dependent ANAVEX ® 2-73 (blarcamesine) target engagement or receptor occupancy with SIGMAR1

in the brain.

Reyes S et al., Sci Rep.

1 unchanged sentence

Cellular Homeostasis

Many diseases are possibly directly caused

by chronic homeostatic imbalances or cellular stress of brain cells.

In pediatric diseases, such as Rett syndrome or infantile

spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.

In neurodegenerative diseases,

such as Alzheimer’s and Parkinson’s diseases, chronic cellular stress is possibly caused by age-correlated buildup

of cellular insult and hence chronic cellular stress.

Specifically, defects in homeostasis of protein or ribonucleic acid (“RNA”)

lead to the death of neurons and dysfunction of the nervous system.

The spreading of protein aggregates resulting in a proteinopathy,

a characteristic found in Alzheimer’s and Parkinson’s diseases that results from disorders of protein synthesis, trafficking,

folding, processing or degradation in cells.

The clearance of macromolecules in the brain is particularly susceptible to imbalances

that result in aggregation and degeneration in nerve cells.

For example, Alzheimer’s disease pathology is characterized by

the presence of amyloid plaques, and neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are

a marker of other diseases known as tauopathies as well as inflammation of microglia.

With the SIGMAR1 activation through SIGMAR1

agonists like ANAVEX ® 2-73 (blarcamesine), our approach is to restore cellular balance (i.e.

Many diseases are possibly directly caused by chronic

homeostatic imbalances or cellular stress of brain cells.

In pediatric diseases, such as Rett syndrome or infantile spasms, chronic cellular

stress is possibly caused by the presence of a constant genetic mutation.

In neurodegenerative diseases, such as Alzheimer’s and

Parkinson’s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular insult and hence chronic

cellular stress.

Specifically, defects in homeostasis of protein or ribonucleic acid (“RNA”) lead to the death of neurons

and dysfunction of the nervous system.

The spreading of protein aggregates resulting in a proteinopathy, a characteristic found in Alzheimer’s

and Parkinson’s diseases that results from disorders of protein synthesis, trafficking, folding, processing or degradation in cells.

The clearance of macromolecules in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in

For example, Alzheimer’s disease pathology is characterized by the presence of amyloid plaques, and neurofibrillary

tangles, which are aggregates of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation

of microglia.

With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX ® 2-73 (blarcamesine), our approach is to

restore cellular balance (i.e.

homeostasis).

that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative

disease progression.

Therapies that correct defects in cellular homeostasis might have the potential to halt or

delay neurodevelopmental and neurodegenerative disease progression.

ANAVEX ® 2-73 (blarcamesine)-specific

As part of some of our clinical trials, we

have incorporated a genomic analysis to better understand potential populations for whom our clinical programs might benefit.

our clinical trials, a full genomic analysis of Alzheimer’s disease patients treated with ANAVEX ® 2-73 (blarcamesine)

has helped us identify actionable genetic variants.

A significant impact of the genomic biomarkers SIGMAR1, the direct target of

ANAVEX ® 2-73 (blarcamesine) and COMT, a gene involved in memory function, on the drug response level was identified,

leading to an early ANAVEX ® 2-73 (blarcamesine)-specific biomarker hypothesis.

We believe that excluding patients

with SIGMAR1 identified biomarker variant (approximately 10%-20% of the population) in prospective studies would identify approximately

80%-90% patients that would display clinically significant improved functional and cognitive scores.

The consistency between the

identified DNA and RNA data related to ANAVEX ® 2-73 (blarcamesine), which are considered independent of Alzheimer’s

disease pathology, as well as multiple endpoints and time-points, provides support for the potential precision medicine clinical

development of ANAVEX ® 2-73 (blarcamesine) by using genetic biomarkers identified within the trial population itself

to target patients who are most likely to respond to ANAVEX ® 2-73 (blarcamesine) treatment.

We may in the future

utilize such an approach in Alzheimer’s disease as well as indications like Parkinson’s disease dementia or Rett syndrome

in which ANAVEX ® 2-73 (blarcamesine) is currently being studied.

As part of some of our clinical trials, we have incorporated

a genomic analysis to better understand potential populations for whom our clinical programs might benefit.

In our clinical trials, a

full genomic analysis of Alzheimer’s disease patients treated with ANAVEX ® 2-73 (blarcamesine) has helped us identify

actionable genetic variants.

A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX ® 2-73 (blarcamesine)

and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX ® 2-73

(blarcamesine) specific biomarker hypothesis.

We believe that excluding patients with SIGMAR1 identified biomarker variant (approximately

10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant

improved functional and cognitive scores.

The consistency between the identified DNA and RNA data related to ANAVEX ® 2-73

(blarcamesine), which are considered independent of Alzheimer’s disease pathology, as well as multiple endpoints and time-points,

provides support for the potential precision medicine clinical development of ANAVEX ® 2-73 (blarcamesine) by using genetic

biomarkers identified within the trial population itself to either confirm the mechanism of action of ANAVEX ® 2-73 (blarcamesine)

or target patients who are most likely to respond to ANAVEX ® 2-73 (blarcamesine) treatment.

We may in the future utilize

such an approach in Alzheimer’s disease as well as indications like Parkinson’s disease dementia in which ANAVEX ® 2-73

(blarcamesine) is currently being studied.

Clinical Trials Overview

2 unchanged sentences

trial, consisting of Part A and Part B, which lasted a total of 57 weeks, for ANAVEX ® 2-73 in mild-to-moderate Alzheimer’s

This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the

safety and exploratory efficacy of ANAVEX ® 2-73 in 32 patients.

ANAVEX ® 2-73 targets sigma-1 and muscarinic

receptors, which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis

and to reverse the pathological hallmarks observed in Alzheimer’s disease.

In October 2017, we presented positive pharmacokinetic

(“PK”) and pharmacodynamic (“PD”) data from the Phase 2a clinical trial, which established a concentration-effect

relationship between ANAVEX ® 2-73 and trial measurements.

These measures obtained from all patients who participated

in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity.

Additionally,

the clinical trial appeared to show that ANAVEX ® 2-73 activity was enhanced by its active metabolite (ANAVEX19-144),

which also targets the SIGMAR1 receptor and has a half-life approximately twice as long as the parent molecule.

Two consecutive trial extensions for the Phase

2a trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX ® 2-73,

providing an opportunity to gather extended safety data for a cumulative time period of five years.

In August 2020, patients completing

these Phase 2a trial extensions were granted continued access to treatment with ANAVEX ® 2-73 through the Australian

Government Department of Health – Therapeutic Goods Administration’s compassionate use Special Access Scheme.

This open-label randomized trial in Australia met both primary and secondary endpoints and was designed to assess the safety

and exploratory efficacy of ANAVEX ® 2-73 in 32 patients.

ANAVEX ® 2-73 targets sigma-1 and muscarinic receptors,

which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse

the pathological hallmarks observed in Alzheimer’s disease.

In October 2017, we presented positive pharmacokinetic (“PK”)

and pharmacodynamic (“PD”) data from the Phase 2a clinical trial, which established a concentration-effect relationship between

ANAVEX ® 2-73 and trial measurements.

These measures obtained from all patients who participated in the entire 57 weeks include

exploratory cognitive and functional scores as well as biomarker signals of brain activity.

Additionally, the clinical trial appeared

to show that ANAVEX ® 2-73 activity was enhanced by its active metabolite (ANAVEX19-144), which also targets the SIGMAR1

receptor and has a half-life approximately twice as long as the parent molecule.

Two consecutive trial extensions for the Phase 2a

trial have allowed participants who completed the 52-week Part B of the trial to continue taking ANAVEX ® 2-73, providing

an opportunity to gather extended safety data for a cumulative time period of five years.

In August 2020, patients completing these Phase

2a trial extensions were granted continued access to treatment with ANAVEX ® 2-73 through the Australian Government Department

of Health – Therapeutic Goods Administration’s compassionate use Special Access Scheme.

A larger Phase 2b/3 double-blind, placebo-controlled

trial of ANAVEX ® 2-73 in Alzheimer’s disease commenced in August 2018.

trial of ANAVEX ® 2-73 in early Alzheimer’s disease commenced in August 2018.

The Phase 2b/3 trial enrolled 508 patients,

which were treated with a convenient once-daily oral formulation of ANAVEX ® 2-73 for 48 weeks, randomized 1:1:1 to

two different ANAVEX ® 2-73 doses or placebo.

which were treated with a convenient once-daily oral formulation of ANAVEX ® 2-73 for 48 weeks, randomized 1:1:1 to two different

ANAVEX ® 2-73 doses or placebo.

The trial took place at 52 sites across North America, Europe and Australia.

Primary and secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer’s

Disease Assessment Scale – Cognitive Subscale test (“ADAS-Cog”), Alzheimer’s Disease Cooperative Study

– Activities of Daily Living (“ADCS-ADL”) and Clinical Dementia Rating – Sum of Boxes for cognition and

function (“CDR-SB”).

In addition to the primary endpoints, the ANAVEX ® 2-73 Phase 2b/3 trial design incorporated

pre-specified statistical analyses related to potential genomic precision medicine biomarkers previously identified in the ANAVEX ® 2-73

Phase 2a clinical trial.

The trial was completed in mid-2022 and, in December 2022, the Company presented positive topline results

from the Phase 2b/3 clinical trial.

ANAVEX ® 2-73 met the co-primary

endpoints ADAS-Cog and ADCS-ADL and key secondary endpoint CDR-SB.

ANAVEX ® 2-73 treatment slowed decline of cognition

and function in patients with early Alzheimer’s disease over 48 weeks.

Patients treated with ANAVEX ® 2-73 had

1.84 times higher odds, or likelihood, to improve cognitively compared to placebo, with a ADAS-Cog score threshold change of -0.5

points or better [Odds Ratio = 1.84 (p = 0.015)].

At clinically significant levels of improvement in function (ADCS-ADL score threshold

change of +3.5 points or better), patients treated with ANAVEX ® 2-73 had 2.67 times higher odds, or likelihood, to

improve function compared to placebo [Odds Ratio = 2.67 (p = 0.0255)].

Additionally, treatment with

ANAVEX ® 2-73 reduced cognitive decline at end of treatment, measured with the ADAS-Cog, as compared to placebo, by

45%, representing a treatment difference in mean score change of -1.85 points (p=0.033).

Compared to placebo, ANAVEX ® 2-73

reduced clinical decline of cognition and function by 27% with mean score difference of -0.42 points (p=0.040) as measured by the

ANAVEX ® 2-73 was generally safe and well tolerated.

All statistical analyses were

performed by outside consultancy companies.

In September 2023, we provided additional

data demonstrating that the clinical effect was complemented by two independent biomarkers.

A significant reduction in pathological

amyloid beta levels in plasma, as well as a significant slowing in the rate of pathological brain atrophy on MRI (Magnetic Resonance

Imaging) scans.

Validated biomarkers of amyloid beta pathology, plasma Aβ42/40 ratio increased significantly (P = 0.048),

demonstrating strong anti-amyloid effects of ANAVEX ® 2-73 in Alzheimer’s disease patients, while MRI revealed

significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing treatment to placebo.

Furthermore, all prespecified clinical

endpoints were further analyzed using a mixed model for repeated measures (MMRM).

Under the multiplicity control rule, a trial

is successful in meeting the co-primary endpoints if the significance of each endpoint is P < 0.05, or if the significance of

only one co-primary endpoint is P < 0.025.

If only one primary endpoint is significant at an α level of 0.025, then the

secondary endpoint will be evaluated at the same level of 0.025.

The trial was successful, since the differences in the least-squares

mean (LSM) change from baseline to 48 weeks between the ANAVEX ® 2-73 and placebo groups were −1.783 [95% CI,

−3.314 to −0.251];

(P = 0.0226) for ADAS-Cog13, and −0.456 [95% CI, −0.831 to −0.080];

for CDR-SB in patients with early Alzheimer’s disease.

In the respective safety population,

common treatment-emergent adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred

in 120 participants (35.8%) during titration and in 76 participants (25.2%) during maintenance with ANAVEX ® 2-73

and 10 (6.0%) during titration and 9 (5.6%) during maintenance with placebo.

A subsequent long-term open label extension

study of ANAVEX ® 2-73, entitled the ATTENTION-AD trial was initiated for patients who have completed the 48-week

Phase 2b/3 placebo-controlled trial referenced above.

This trial extension for an additional 96 weeks is currently ongoing, and

provides an opportunity to evaluate longer term safety and efficacy of ANAVEX ® 2-73 in persons with Alzheimer’s

secondary endpoints to assess safety and both cognitive and functional efficacy, were measured through the Alzheimer’s Disease Assessment

Scale – Cognitive Subscale test (“ADAS-Cog”), Alzheimer’s Disease Cooperative Study – Activities of Daily

Living (“ADCS-ADL”) and Clinical Dementia Rating – Sum of Boxes for cognition and function (“CDR-SB”).

addition to these endpoints, the ANAVEX ® 2-73 Phase 2b/3 trial design incorporated pre-specified statistical analyses related

to potential genomic precision medicine biomarkers previously identified in the ANAVEX ® 2-73 Phase 2a clinical trial.

trial was completed in mid-2022 and, in December 2022, the Company presented topline results from the Phase 2b/3 clinical trial.

All statistical

analyses were performed by outside consultancy companies.

Furthermore, all pre-specified clinical endpoints were analyzed using a mixed model

for repeated measures (MMRM).

Under the multiplicity control rule, a trial is successful in meeting the co-primary endpoints if the significance

of each endpoint is P < 0.05, or if the significance of only one co-primary endpoint is P < 0.025.

If only one primary endpoint

is significant at an α level of 0.025, then the secondary endpoint will be evaluated at the same level of 0.025.

The trial was successful,

the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the ANAVEX ® 2-73 and placebo groups

for ADAS-Cog13 was significant at a level of P < 0.025 and for CDR-SB was significant at a level of P < 0.025, in the patients with

early Alzheimer’s disease.

The comparison of individual dose groups vs placebo

also supports blarcamesine’s efficacy.

For the primary endpoint ADAS-Cog13, blarcamesine is significantly better than placebo (−2.027;

P = 0.0079) as well as for both the 50 mg (−2.149;

P = 0.021) and the 30 mg (−1.934;

P = 0.026) blarcamesine dosage groups

at Week 48, representing that blarcamesine slowed clinical progression at 48 weeks by 36.3% and by 38.5% and 34.6% in 50 mg and 30 mg

placebo, respectively.

The functional co-primary endpoint, ADCS-ADL, was trending in a positive direction but did not reach

significance at Week 48.

The key secondary endpoint CDR-SB was significantly improved vs.

placebo (−0.483, P = 0.0104) as well as

in both 50 mg (−0.465;

P = 0.045) and 30 mg (−0.502;

P = 0.020) groups at Week 48.

Clinical Global Impression – Improvement

(“CGI-I”) was also significantly improved vs.

placebo (−0.278, P = 0.004) as well as in both the 50 mg (−0.314;

P = 0.008) and the 30 mg (−0.248;

P = 0.024) groups at Week 48.

The findings are supported by biomarkers, including plasma Aβ42/40-ratio

and reduction of brain atrophy.

Blarcamesine significantly slowed brain atrophy in key regions of interest, including the whole brain

by 37.6%, total grey matter by 63.5%, and lateral ventricles by 25.1%.

In the respective safety population, common treatment-emergent

adverse events included dizziness, which was transient and mostly mild to moderate in severity, and occurred in 120 participants (35.8%)

during titration and in 76 participants (25.2%) during maintenance with ANAVEX ® 2-73 and 10 (6.0%) during titration and

9 (5.6%) during maintenance with placebo.

In November 2024, we announced the submission of a

Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for ANAVEX ® 2-73 for the treatment of

Alzheimer's disease and, in December 2024, the EMA accepted the submission for scientific review.

The MAA, if approved, would allow direct

market access throughout the European Union for oral ANAVEX ® 2-73 (blarcamesine) for the treatment of Alzheimer’s

A subsequent long-term open label extension study

of ANAVEX ® 2-73, referred to as the ATTENTION-AD trial, was initiated for patients who completed the 48-week Phase 2b/3

placebo-controlled trial referenced above.

This trial extension for a duration of up to 96/144 additional weeks was completed in June

The trial extension will provide additional longer-term safety and efficacy data of ANAVEX ® 2-73 in persons with early

Alzheimer’s disease.

Rett Syndrome

1 unchanged sentence

data for ANAVEX ® 2-73 in Rett syndrome, a rare neurodevelopmental disease.

The data demonstrated dose related and

significant improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes

neurological symptoms that mimic Rett syndrome.

The data demonstrated dose related significant

improvements in an array of behavioral and gait paradigms in a mouse model with an MECP2-null mutation that causes neurological symptoms

that mimic Rett syndrome.

The study was funded by the International Rett Syndrome Foundation (“Rettsyndrome.org”).

In January 2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs

of a multicenter Phase 2 clinical trial of ANAVEX ® 2-73 for the treatment of Rett syndrome.

This award was received

in quarterly instalments which commenced during fiscal 2018.

2017, we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter

Phase 2 clinical trial of ANAVEX ® 2-73 for the treatment of Rett syndrome.

In March 2019, we commenced the first Phase 2

clinical trial in a planned Rett syndrome program of ANAVEX ® 2-73 for the treatment of Rett syndrome.

trials are being conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation

trials were conducted in a range of patient age demographics and geographic regions, utilizing an oral liquid once-daily formulation

of ANAVEX ® 2-73.

1 unchanged sentence

which took place in the United States, was completed in December 2020.

This trial was a randomized double-blind, placebo-controlled

safety, tolerability, PK and efficacy trial of oral liquid ANAVEX ® 2-73 formulation in 25 adult female patients with

Rett syndrome over a 7-week treatment period including ANAVEX ® 2-73-specific genomic precision medicine biomarkers.

The primary endpoint of the trial was safety.

The dosing of 5 mg ANAVEX ® 2-73 was well-tolerated and demonstrated

dose-proportional PK.

All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful

response in the Rett Syndrome Behaviour Questionnaire (“RSBQ”) response, when compared to placebo, in the intent to

treat (“ITT”) cohort (all participants, p = 0.011).

66.7% of ANAVEX ® 2-73 treated subjects showed a statistically

significant improvement in RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort (all participants, p =

ANAVEX ® 2-73 treatment resulted in a sustained improvement in Clinical Global Impression Improvement (CGI-I)

response throughout the 7-week clinical trial, when compared to placebo in the ITT cohort (all participants, p = 0.014).

with previous ANAVEX ® 2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX ® 2-73

experienced stronger improvements in the prespecified efficacy endpoints.

second, international trial of ANAVEX ® 2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced

in June 2019.

This trial was a randomized double-blind, placebo-controlled safety,

tolerability, PK and efficacy trial of oral liquid ANAVEX ® 2-73 formulation in 25 adult female patients with Rett syndrome

over a 7-week treatment period including ANAVEX ® 2-73-specific genomic precision medicine biomarkers.

The primary endpoint

of the trial was safety.

The dosing of 5 mg ANAVEX ® 2-73 was well-tolerated and demonstrated dose-proportional PK.

All secondary

efficacy endpoints of the trial showed statistically significant and clinically meaningful response in the Rett Syndrome Behaviour Questionnaire

(“RSBQ”) response, when compared to placebo, in the intent to treat (“ITT”) cohort (all participants, p = 0.011).

66.7% of ANAVEX ® 2-73 treated subjects showed a statistically significant improvement in RSBQ response as compared to 10%

of the subjects on placebo in the ITT cohort (all participants, p = 0.011).

ANAVEX ® 2-73 treatment resulted in a sustained

improvement in CGI-I response throughout the 7-week clinical trial, when compared to placebo in the ITT cohort (all participants, p =

Consistent with previous ANAVEX ® 2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated

with ANAVEX ® 2-73 experienced stronger improvements in the prespecified efficacy endpoints.

No other clinical trials with

ANAVEX ® 2-73 related to Rett syndrome have been conducted in the United States.

second, international trial of ANAVEX ® 2-73 for the treatment of Rett syndrome, called the AVATAR trial, commenced in June

This trial took place in Australia and the United Kingdom using a higher dose than the U.S.

based Phase 2

trial for Rett syndrome.

The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and

efficacy of ANAVEX ® 2-73 in 33 adult patients over a 7-week treatment period including ANAVEX ® 2-73

specific precision medicine biomarkers.

Based upon the input from the successful U.S.

Phase 2 Rett syndrome trial (ANAVEX ® 2-73-RS-001),

we updated the endpoints for the AVATAR trial (ANAVEX ® 2-73-RS-002) to appropriately assess the clinically meaningful

outcome following International Conference on Harmonization (ICH) guidelines.

These updates were approved by the respective regulatory

authorities in the U.K.

and in Australia, respectively, where the AVATAR trial was conducted.

The data from the AVATAR trial was released

in February 2022.

The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements

in primary efficacy endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, ADAMS (p = 0.010) and CGI-I (p = 0.037)

Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms.

based Phase 2 trial for Rett

The trial was a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of ANAVEX ® 2-73

in 33 adult patients over a 7-week treatment period including ANAVEX ® 2-73 specific precision medicine biomarkers.

upon the input from the successful U.S.

Phase 2 Rett syndrome trial (ANAVEX ® 2-73-RS-001), we updated the endpoints for

the AVATAR trial (ANAVEX ® 2-73-RS-002) to appropriately assess the clinically meaningful outcome following International

Conference on Harmonization (ICH) guidelines.

These updates were approved by the respective regulatory authorities in the U.K.

Australia, respectively, where the AVATAR trial was conducted.

The data from the AVATAR trial was released in February

The clinical trial met all primary and secondary efficacy and safety endpoints, with consistent improvements in primary efficacy

endpoint, RSBQ response (p = 0.037), and secondary efficacy endpoints, Anxiety, Depression, and Mood Scale (ADAMS) (p = 0.010) and CGI-I

(p = 0.037) response.

Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome

Convenient once daily oral liquid doses of up to 30 mg of ANAVEX ® 2-73 were also well tolerated with good medication

All patients who participated in the trial were eligible to receive ANAVEX ® 2-73 under a voluntary open

label extension protocol.

In July 2020, we commenced the third trial

of ANAVEX ® 2-73 for the treatment of Rett syndrome, called the EXCELLENCE trial.

This Phase 2/3 trial in pediatric

patients with Rett syndrome includes trial sites in Australia, the United Kingdom and Canada, and will evaluate the safety and

efficacy of ANAVEX ® 2-73 in approximately 84 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating

ANAVEX ® 2-73 specific precision medicine biomarkers.

This trial completed enrollment in February 2023, exceeding

the original enrollment target.

In June 2023, this trial completed dosing of all participants, and topline results are expected

in the second half of 2023.

All patients who participate in the trial will be eligible to receive ANAVEX ® 2-73 under

a voluntary open label extension protocol, which is currently ongoing.

All patients who participated in the trial were eligible to receive ANAVEX ® 2-73 under a voluntary open label

extension protocol and subsequent Compassionate Use Program.

The very first trial of ANAVEX ® 2-73

in pediatric Rett syndrome patients, the EXCELLENCE trial, completed enrollment in February 2023.

This randomized, double-blind, placebo-controlled

Phase 2/3 trial in pediatric patients with Rett syndrome included trial sites in Canada, Australia, and the United Kingdom.

patients with Rett syndrome between the ages of 5 through 17 years were treated daily with up to 30 mg ANAVEX ® 2-73.

were randomized 2:1 (ANAVEX ® 2-73:placebo) for 12 weeks, followed by a week 16 safety visit and topline results from this

trial were announced in early January 2024.

After 12 weeks, the study showed improvement on the

key co-primary endpoint RSBQ, which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients’

The other co-primary endpoint, the CGI-I, which represents a less granular assessment by the site investigators using a seven-point

scoring (one=“very much improved” to seven=“very much worse”), was not met.

In an ad-hoc analysis, using the predefined mixed-effect

model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX ® 2-73-treated patients improved LS Mean (SE)

-12.93 (2.150) points on their RSBQ total score compared to LS Mean (SE) -8.32 (2.537) points in placebo-treated patients.

difference (SE) of -4.61 (2.439) points between treated and placebo groups did not reach statistical significance (n=77;

ANAVEX ® 2-73-treated

patients demonstrated a rapid onset of action with improvements at 4 weeks after treatment with a RSBQ total score LS Mean (SE) -10.32

(2.086) points in the drug-treated group compared to a LS Mean (SE) -5.67 (2.413) points in placebo-treated patients.

The LS Mean difference

of -4.65 (2.233) points between treated and placebo groups was statistically significant (n=77;

The key secondary endpoint, the ADAMS, trended favorably.

In the same analysis, scores for all RSBQ and ADAMS subscales improved over the course of the study.

Collectively, the RSBQ and ADAMS

demonstrated improvements in multiple areas, impacting positively in particular repetitive movements, nighttime disruptive behaviors,

and social avoidance.

A preliminary review of the safety results indicates

there were no new safety signals in the EXCELLENCE study, reinforcing the favorable and manageable safety profile observed with ANAVEX ® 2-73

All patients who participated in the trial were eligible

to receive ANAVEX ® 2-73 under a voluntary open label extension protocol, which was completed in June 2024.

A high enrollment rate in the Open Label Extension

(“OLE”) of over 91% and the high level of requests for the Compassionate Use Program (93%) provide solid numerical evidence

for the reported positive Real World Evidence (RWE) from patients with Rett syndrome under Compassionate Use Authorization.

Families whose

children were previously on drug or placebo in the placebo-controlled trial commented favorably on the improvement of their child’s

daily life due to ANAVEX ® 2-73 treatment in the Compassionate Use Program.

Parkinson’s Disease

In September 2016, we presented positive preclinical

data for ANAVEX ® 2-73 in an animal model of Parkinson’s disease, which demonstrated significant improvements

on behavioral, histopathological, and neuroinflammatory endpoints.

data for ANAVEX ® 2-73 in an animal model of Parkinson’s disease, which demonstrated significant improvements on behavioral,

histopathological, and neuroinflammatory endpoints.

The study was funded by the Michael J.

Fox Foundation.

data announced in October 2017 indicated that ANAVEX ® 2-73 induced robust neurorestoration in experimental Parkinsonism.

We believe the encouraging results we have gathered in this preclinical model, coupled with the favorable profile of this product

candidate in the Alzheimer’s disease trial, support the notion that ANAVEX ® 2-73 has the potential to treat

Parkinson’s disease dementia.

In October 2020, we completed a double-blind,

randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s disease dementia

in Spain and Australia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.

The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73

doses, 30 mg and 50 mg, or placebo.

The ANAVEX ® 2-73 Phase 2 Parkinson’s disease dementia trial design incorporated

genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a Alzheimer’s disease trial.

Additional data announced in

October 2017 indicated that ANAVEX ® 2-73 induced robust neurorestoration in experimental Parkinsonism.

We believe the encouraging

results we have gathered in this preclinical model, coupled with the favorable profile of this product candidate in the Alzheimer’s

disease trial, support the notion that ANAVEX ® 2-73 has the potential to treat Parkinson’s disease dementia.

In October 2020, we completed a double-blind, randomized,

placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s disease dementia in Spain and Australia,

to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.

The Phase 2 trial enrolled

approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73 doses, 30 mg and 50 mg, or placebo.

The ANAVEX ® 2-73 Phase 2 Parkinson’s disease dementia trial design incorporated genomic precision medicine biomarkers

identified in the ANAVEX ® 2-73 Phase 2a Alzheimer’s disease trial.

The trial demonstrated that ANAVEX ® 2-73

was safe and well tolerated in oral doses up to 50 mg once daily.

The results showed clinically meaningful, dose-dependent, and

statistically significant improvements in the Cognitive Drug Research (“CDR”) computerized assessment system analysis.

Treatment with ANAVEX ® 2-73 also resulted in clinically meaningful improvements as measured by the global composite

score of Parkinson’s disease symptom severity, MDS-Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”)

total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications after 14 weeks of

treatment, suggesting ANAVEX ® 2-73’s potential capability of slowing and reversing symptoms that progress in

Parkinson’s disease.

In addition, the trial confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker

in response to ANAVEX ® 2-73 may result in improved clinical outcomes.

A 48-week Open Label Extension (“OLE”)

ANAVEX2-73-PDD-EP-001 Phase 2 trial was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001

Phase 2 trial discussed above.

The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson’s

Disease Rating Scale Parts I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Clinical Global Impression

– Improvement (CGI-I), as well as cognitive efficacy endpoint Montreal Cognitive Assessment (MoCA) over a 48-week period.

In March 2023, we reported the preliminary

ANAVEX2-73-PDD-EP-001 OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX ® 2-73 on the prespecified

primary and secondary objectives.

Preliminary analysis reveals that ANAVEX ® 2-73 was found to be generally safe and

well tolerated;

and safety findings in this trial were consistent with the known safety profile of ANAVEX ® 2-73.

In respect to efficacy, across all efficacy endpoints, patients performed better while on ANAVEX ® 2-73.

patients were on drug holiday due to COVID-19 between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including

the MDS-UPDRS Part II + III and CGI-I, measured at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were

worsening, as expected in a progressive disease like Parkinson’s.

However, when patients resumed daily oral ANAVEX ® 2-73

treatment, a consistent improvement was observed during the extension phase from OLE Baseline through OLE Week 24, and OLE Week

48, respectively.

These results are consistent with the pattern observed for all efficacy measures in the extension phase.

two endpoints, MDS-UPDRS Part II + III and CGI-I measured in this study are the planned primary and key secondary endpoints in

our forthcoming pivotal 6-month Parkinson’s disease study.

In January 2021, we were awarded a research

grant of $1.0 million from The Michael J.

Fox Foundation for Parkinson’s Research to develop ANAVEX ® 2-73

for the treatment of Parkinson’s disease.

The award will explore utilization of PET imaging biomarkers to enable measurement

of target engagement and pathway activation of the SIGMAR1 with clinically relevant doses, including in people with Parkinson’s

Schizophrenia, Frontotemporal Dementia and

Alzheimer’s disease

In July 2020, we commenced the First-in-Human

Phase 1 clinical trial of ANAVEX ® 3-71.

ANAVEX ® 3-71 was previously granted orphan drug designation

for the treatment of Frontotemporal Dementia (“FTD”) by the FDA.

ANAVEX ® 3-71 is an orally administered

small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.

In preclinical studies, ANAVEX ® 3-71 demonstrated disease-modifying activity

against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and

tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.

The results showed clinically meaningful, dose-dependent, and statistically

significant improvements in the Cognitive Drug Research (“CDR”) computerized assessment system analysis.

Treatment with ANAVEX ® 2-73

also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson’s disease symptom severity,

MDS-Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) total score on top of standard of care including dopaminergic

therapy, levodopa and other anti-PD medications after 14 weeks of treatment, suggesting ANAVEX ® 2-73’s potential capability

of slowing and reversing symptoms that progress in Parkinson’s disease.

In addition, the trial confirmed the precision medicine

approach of targeting SIGMAR1 as a genetic biomarker in response to ANAVEX ® 2-73 may result in improved clinical outcomes.

A 48-week OLE ANAVEX2-73-PDD-EP-001 Phase 2 trial

was offered to participants after completion of the double-blind placebo-controlled ANAVEX2-73-PDD-001 Phase 2 trial discussed above.

The OLE trial assessed safety, tolerability and efficacy, measuring among others, MDS-Unified Parkinson’s Disease Rating Scale Parts

I, II, III, REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ), CGI-I, as well as cognitive efficacy endpoint Montreal Cognitive

Assessment (MoCA) over a 48-week period.

In March 2023, we reported the preliminary ANAVEX2-73-PDD-EP-001

OLE trial data, which demonstrated longitudinal beneficial effects of ANAVEX ® 2-73 on the pre-specified primary and secondary

Preliminary analysis reveals that ANAVEX ® 2-73 was found to be generally safe and well tolerated, and safety

findings in this trial were consistent with the known safety profile of ANAVEX ® 2-73.

In respect to efficacy, across all

efficacy endpoints, patients performed better while on ANAVEX ® 2-73.

While all patients were on drug holiday due to COVID-19

between the DB EOT and the OLE Baseline, the respective efficacy endpoints, including the MDS-UPDRS Part II + III and CGI-I, measured

at the end of trial of the double-blind study (DB EOT) and the OLE Baseline, were worsening, as expected in a progressive disease like

However, when patients resumed daily oral ANAVEX ® 2-73 treatment, a consistent improvement was observed

during the extension phase from OLE Baseline through OLE Week 24, and OLE Week 48, respectively.

These results are consistent with the

pattern observed for all efficacy measures in the extension phase.

The two endpoints, MDS-UPDRS Part II + III and CGI-I measured in this

study are the planned primary and key secondary endpoints in our forthcoming >6-month Parkinson’s disease study.

In January 2021, we were awarded a research grant

of $1.0 million from The Michael J.

Fox Foundation for Parkinson’s Research to develop ANAVEX ® 2-73 for

the treatment of Parkinson’s disease.

The award will explore utilization of PET imaging biomarkers to enable measurement of target

engagement and pathway activation of the SIGMAR1 with clinically relevant doses including in people with Parkinson’s disease.

Schizophrenia, Frontotemporal Dementia and Alzheimer’s

In July 2020, we commenced the First-in-Human Phase

1 clinical trial of ANAVEX ® 3-71.

ANAVEX ® 3-71 was previously granted orphan drug designation for the treatment

of Frontotemporal Dementia (“FTD”) by the FDA.

ANAVEX ® 3-71 is an orally administered small molecule targeting

sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.

In preclinical studies, ANAVEX ® 3-71

demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including

cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.

clinical trial was a prospective double-blind, randomized, placebo-controlled trial in Australia.

A total of 36 healthy male

and female subjects were included.

Single escalating doses of ANAVEX ® 3-71 were administered in order to evaluate

the safety, tolerability, and PK of ANAVEX ® 3-71 and the effects of food and gender on its PK in healthy volunteers.

met its primary and secondary endpoints of safety, with no serious adverse events (“SAEs”) or dose-limiting toxicities

ANAVEX ® 3-71 was well tolerated in all cohorts receiving ANAVEX ® 3-71 in single doses ranging

from 5 mg to 200 mg daily with no SAEs and no significant lab abnormalities in any subject.

In the trial, ANAVEX ® 3-71

exhibited linear PK.

A total of 36 healthy male and female

subjects were included.

Single escalating doses of ANAVEX ® 3-71 were administered in order to evaluate the safety, tolerability,

and PK of ANAVEX ® 3-71 and the effects of food and gender on its PK in healthy volunteers.

The trial met

its primary and secondary endpoints of safety, with no serious adverse events (“SAEs”) or dose-limiting toxicities observed.

ANAVEX ® 3-71 was well tolerated in all cohorts receiving ANAVEX ® 3-71 in single doses ranging from 5 mg to

200 mg daily with no SAEs and no significant lab abnormalities in any subject.

In the trial, ANAVEX ® 3-71 exhibited linear

Its pharmacokinetics was also dose proportional for doses up to 160 mg.

Gender had no effect on the PK of

the drug and food had no effect on the bioavailability of ANAVEX ® 3-71.

The trial also met the secondary objective

of characterizing the effect of ANAVEX ® 3-71 on electrocardiogram (“ECG”) parameters.

There were no clinically

significant ECG parameters throughout the trial.

Participant QTcF measures were normal across all dose groups with no difference

between ANAVEX ® 3-71 and placebo.

Gender had no effect on the PK of the drug and food had no

effect on the bioavailability of ANAVEX ® 3-71.

The trial also met the secondary objective of characterizing the effect of

ANAVEX ® 3-71 on electrocardiogram (“ECG”) parameters.

There were no clinically significant ECG parameters throughout

Participant QTcF measures were normal across all dose groups with no difference between ANAVEX ® 3-71 and placebo.

In October 2023

a peer-reviewed publication in the journal Neurobiology of Aging , titled ‘ Early treatment with an M1 and sigma-1 receptor

1 unchanged sentence

available small molecule ANAVEX ® 3-71 (AF710B).

The preclinical study described the potential disease-modifying

properties of ANAVEX ® 3-71 on Alzheimer’s disease pathology as a possible drug candidate for a potential once

daily oral preventive strategy for Alzheimer’s disease.

on these results, and ANAVEX ® 3-71’s pre-clinical profile, we intend to advance ANAVEX ® 3-71

into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer’s disease,

evaluating longitudinal effect of treatment with ANAVEX ® 3-71.

We believe the results of these clinical trials and

preclinical study could serve as a basis for advancing into respective registration trials in the U.S.

Our research and development pipeline includes

ANAVEX ® 2-73 currently in three different clinical trial indications, and several other compounds in different stages

of clinical and pre-clinical development.

Our proprietary SIGMACEPTOR™ Discovery

Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors.

receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s

disease, as well as of neurodevelopmental nature, like Rett syndrome.

When bound by the appropriate ligands, sigma receptors influence

the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular

processes, in order to ensure survival and replication.

Hence, it is possible that SIGMAR1 could play a role in modulating the

cellular response to viral infection and ameliorate pathogenesis.

The preclinical study described the potential disease-modifying properties

of ANAVEX ® 3-71 on Alzheimer’s disease pathology as a possible drug candidate for a potential once daily oral preventive

strategy for Alzheimer’s disease.

In January 2024,

in another peer-reviewed publication in the journal Clinical Pharmacology in Drug Development , entitled, ‘ Population-Based

Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor

Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease’ , reported the population-based

characterization of the PK and food effect of ANAVEX ® 3-71 as part of the single ascending dose study in healthy participants

with the primary objective of assessing dose proportionality of ANAVEX ® 3-71, and to characterize the effect of food on

the PK of ANAVEX ® 3-71.

The results from this PK evaluation demonstrated that ANAVEX ® 3-71, at single ascending

doses of 5 to 200 mg, is linear, dose proportional, and time invariant.

Food had no effect on the PK of ANAVEX ® 3-71.

data also expands the safety objectives met in this first-in-human study of ANAVEX ® 3-71, further supporting its drug development

Based on these

results, and ANAVEX ® 3-71’s pre-clinical profile, we intend to advance ANAVEX ® 3-71 into a biomarker-driven

clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer’s disease, evaluating longitudinal effect

of treatment with ANAVEX ® 3-71.

Schizophrenia

In March 2024,

we commenced the U.S.

FDA-cleared ANAVEX ® 3-71-SZ-001 clinical trial:

a double-blind, placebo-controlled Phase 2 trial in

schizophrenia.

The trial consists of two parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day

treatment period in a larger cohort.

The trial will utilize standard clinical outcome measures for schizophrenia including the Positive

and Negative Symptoms Scale (PANSS), and novel fluid and electrophysiological biomarkers will also be assessed, leveraging several advances

in electroencephalography/event-related potential (EEG/ERP) biomarkers in schizophrenia developed in collaboration with the industry-led

ERP Biomarker Qualification Consortium.

In addition to the electrophysiological biomarkers, we are also applying novel neuroinflammatory,

metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX ® 3-71’s

novel, dual mechanism of action.

results from Part A of the ANAVEX ® 3-71-SZ-001 clinical trial, consisting of a multiple ascending dose study in 16 participants,

demonstrated a dose-dependent effect of ANAVEX ® 3-71 on two key EEG biomarkers in patients with schizophrenia.

were most pronounced in the higher dose group indicating a dose-dependent pharmacodynamic effect.

The observed changes reversed known

electroencephalography (EEG) and ERP biomarker abnormalities associated with schizophrenia.

These EEG biomarkers correlate with positive,

negative, and cognitive symptoms of schizophrenia.

The currently

ongoing Part B of the placebo-controlled Phase 2 study, which includes more participants and a longer treatment duration, will provide

more comprehensive data on the efficacy and safety of ANAVEX ® 3-71 in schizophrenia.

Our research and development pipeline includes ANAVEX ® 2-73

currently in three different clinical trial indications, and ANAVEX ® 3-71 currently in one clinical trial and several other

compounds in different stages of clinical and pre-clinical development.

Our proprietary SIGMACEPTOR™ Discovery Platform

produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors.

Sigma receptors may

be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s disease, as well

as of neurodevelopmental nature, like Rett syndrome.

When bound by the appropriate ligands, sigma receptors influence the functioning

of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Multiple viruses including SARS-CoV-2

(COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular processes, in order to ensure survival

and replication.

Hence, it is possible that SIGMAR1 could play a role in modulating the cellular response to viral infection and ameliorate

pathogenesis.

Compounds that have been subjects of our research

1 unchanged sentence

ANAVEX ® 2-73 (blarcamesine)

We believe ANAVEX ® 2-73 may offer

a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1.

ANAVEX ® 2-73

is being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily

capsule formulation for diseases such as Alzheimer’s disease.

We believe ANAVEX ® 2-73 may offer a

disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1.

ANAVEX ® 2-73 is

being developed in an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule

formulation for diseases such as Alzheimer’s disease.

In Rett syndrome, administration of ANAVEX ® 2-73

in liquid form resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET

Rett syndrome disease model.

In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX ® 2-73 was

evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident.

Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice.

Treatment with ANAVEX ® 2-73

for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome disease mice.

Additionally, chronic

oral dosing daily for 6.5 weeks of ANAVEX ® 2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett

syndrome disease mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths,

some of the core deficits observed in Rett syndrome.

Administration of ANAVEX ® 2-73 resulted in both significant

and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.

In May 2016 and June 2016, the FDA granted

Orphan Drug Designation to ANAVEX ® 2-73 for the treatment of Rett syndrome and infantile spasms, respectively.

November 2019, the FDA granted to ANAVEX ® 2-73 the Rare Pediatric Disease (RPD) designation for the treatment of

Rett syndrome.

The RPD designation is intended to encourage the development of treatments for rare pediatric diseases.

Further, in February 2020, the FDA granted

Fast Track designation for the ANAVEX ® 2-73 clinical development program for the treatment of Rett syndrome.

FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical

needs in the treatment of serious and life-threatening conditions.

For Parkinson’s disease, data demonstrates

significant improvements and restoration of function in a disease-modifying animal model of Parkinson’s disease.

improvements were seen on all measures tested:

in liquid form resulted in both significant and dose-related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome

disease model.

In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX ® 2-73 was evaluated in automatic

visual response and respiration tests in 7-month-old mice, an age at which advanced pathology is evident.

Vehicle-treated MECP2 mice demonstrated

fewer automatic visual responses than wild-type mice.

Treatment with ANAVEX ® 2-73 for four weeks significantly increased

the automatic visual response in the MECP2 Rett syndrome disease mice.

Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX ® 2-73

starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular

coordination, balance, motor learning and muscular strengths, some of the core deficits observed in Rett syndrome.

Administration of ANAVEX ® 2-73

resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease

In May 2016 and June 2016, the FDA granted Orphan

Drug Designation to ANAVEX ® 2-73 for the treatment of Rett syndrome and infantile spasms, respectively.

In November 2019,

the FDA granted ANAVEX ® 2-73 the Rare Pediatric Disease (RPD) designation for the treatment of Rett syndrome.

The RPD designation

is intended to encourage the development of treatments for rare pediatric diseases.

Further, in February 2020, the FDA granted Fast Track

designation for the ANAVEX ® 2-73 clinical development program for the treatment of Rett syndrome.

The FDA Fast Track program

is designed to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of serious

and life-threatening conditions.

For Parkinson’s disease, data demonstrates significant

improvements and restoration of function in a disease modifying animal model of Parkinson’s disease.

Significant improvements were

seen on all measures tested:

behavioral, histopathological, and neuroinflammatory endpoints.

In October 2020,

we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s

disease dementia, to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.

The Phase 2 trial enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73

doses, 30mg and 50mg, or placebo.

The ANAVEX ® 2-73 Phase 2 Parkinson’s disease dementia trial design incorporated

genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a Alzheimer’s disease trial.

In October 2020, we completed a double-blind,

randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX ® 2-73 in Parkinson’s disease dementia, to

study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.

The Phase 2 trial enrolled approximately

132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX ® 2-73 doses, 30 mg and 50 mg, or placebo.

The ANAVEX ® 2-73

Phase 2 Parkinson’s disease dementia trial design incorporated genomic precision medicine biomarkers identified in the ANAVEX ® 2-73

Phase 2a Alzheimer’s disease trial.

The trial demonstrated that ANAVEX ® 2-73

was safe and well tolerated in oral doses up to 50 mg once daily.

The results showed clinically meaningful, dose-dependent, and

statistically significant improvements in the CDR computerized assessment system analysis.

We anticipate conducting further clinical

trials of ANAVEX ® 2-73 in Parkinson’s disease dementia after submitting the results of the trial to the FDA

to obtain regulatory guidance.

In Alzheimer’s disease animal models,

ANAVEX ® 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,

anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type

muscarinic receptors.

In addition, ANAVEX ® 2-73 has shown a potential dual mechanism which may impact amyloid, tau

pathology and inflammation.

In a transgenic Alzheimer’s disease animal model Tg2576, ANAVEX ® 2-73 induced a

statistically significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly

increased the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent.

It also statistically

alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working

memory and long-term spatial reference memory.

Based on the results of pre-clinical testing,

we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX ® 2-73.

In this Phase 1

SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg.

This dose is above the equivalent dose shown

to have positive effects in mouse models of Alzheimer’s disease.

The results showed clinically meaningful, dose-dependent, and statistically

significant improvements in the CDR computerized assessment system analysis.

We anticipate conducting further clinical trials of ANAVEX ® 2-73

in Parkinson’s disease dementia after submitting the results of the trial to regulatory authorities to obtain regulatory guidance.

In Alzheimer’s disease animal models, ANAVEX ® 2-73

has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive

therapeutic agent, due to its potent affinity to SIGMAR1 and moderate affinities to M1-4 type muscarinic receptors.

In addition, ANAVEX ® 2-73

has shown a potential dual mechanism which may impact amyloid, tau pathology and inflammation.

In a transgenic Alzheimer’s disease

animal model Tg2576, ANAVEX ® 2-73 induced a statistically significant neuroprotective effect against the development of

oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that

is apparently amyloid-beta independent.

It also statistically alleviated the learning and memory deficits developed over time in the animals,

regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.

Based on the results of pre-clinical testing, we initiated

and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX ® 2-73.

In this Phase 1 SAD trial, the maximum

tolerated single dose was defined per protocol as 55-60 mg.

This dose is above the equivalent dose shown to have positive effects in mouse

models of Alzheimer’s disease.

There were no significant changes in laboratory or ECG parameters.

ANAVEX ® 2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects.

adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity

and reversible.

These side effects are often seen with drugs that target CNS conditions, including Alzheimer’s disease.

ANAVEX ® 2-73 was

well tolerated below the 55-60 mg dose with only mild adverse events in some subjects.

Observed adverse events at doses above the maximum

tolerated single dose included headache and dizziness, which were moderate in severity and reversible.

These side effects are often seen

with drugs that target CNS conditions, including Alzheimer’s disease.

In November 2016, we completed a Phase 2a clinical

trial for ANAVEX ® 2-73, for the treatment of Alzheimer’s disease.

The open-label randomized trial was designed

to assess the safety and exploratory efficacy of ANAVEX ® 2-73 in 32 patients with mild-to-moderate Alzheimer’s

The open-label randomized trial was designed to

assess the safety and exploratory efficacy of ANAVEX ® 2-73 in 32 patients with mild-to-moderate Alzheimer’s disease.

The Phase 2a trial met both primary and secondary objectives of the trial.

1 unchanged sentence

the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a clinical trial.

More than 33,000 genes were

analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients

treated with ANAVEX ® 2-73.

The analysis identified genetic variants that impacted response to ANAVEX ® 2-73,

among them variants related to the SIGMAR1, the target for ANAVEX ® 2-73.

Results showed that trial participants with

the common SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved

cognitive (MMSE) and functional (ADCS-ADL) scores.

The results from this evaluation supported the continued evaluation of genomic

information in subsequent clinical trials, since these signatures can now be applied to neurological indications tested in future

clinical trials with ANAVEX ® 2-73 including Alzheimer’s disease, Parkinson’s disease dementia and Rett

More than 33,000 genes were analyzed

using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA and RNA data in patients treated

with ANAVEX ® 2-73.

The analysis identified genetic variants that impacted response to ANAVEX ® 2-73, among

them variants related to the SIGMAR1, the target for ANAVEX ® 2-73.

Results showed that trial participants with the common

SIGMAR1 wild type gene variant, which is estimated to be about 80% of the population worldwide, demonstrated improved cognitive (MMSE)

and functional (ADCS-ADL) scores.

The results from this evaluation supported the continued evaluation of genomic information in subsequent

clinical trials, since these signatures can now be applied to neurological indications tested in future clinical trials with ANAVEX ® 2-73

including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome.

ANAVEX ® 2-73

1 unchanged sentence

On July 2, 2018, the Human Research

Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety

and efficacy trial of ANAVEX ® 2-73 for the treatment of early Alzheimer’s disease.

Clinical trial sites in

Canada, the United Kingdom, the Netherlands and Germany were also added.

This Phase 2b/3 trial design incorporates inclusion of

genomic precision medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a trial.

We believe preclinical data from our studies

also supports further research into the use of ANAVEX ® 2-73 as a potential platform drug for other neurodegenerative

diseases beyond Alzheimer’s disease, Parkinson’s disease or Rett syndrome, more specifically, epilepsy, infantile spasms,

Fragile X syndrome, Angelman syndrome, multiple sclerosis, and, more recently, tuberous sclerosis complex (TSC).

ANAVEX ® 2-73

demonstrated significant improvements in all of these indications in the respective preclinical animal models.

Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety and

efficacy trial of ANAVEX ® 2-73 for the treatment of early Alzheimer’s disease.

Clinical trial sites in Canada, the

United Kingdom, the Netherlands and Germany were also added.

This Phase 2b/3 trial design incorporates inclusion of genomic precision

medicine biomarkers identified in the ANAVEX ® 2-73 Phase 2a trial.

We believe preclinical data from our studies also

supports further research into the use of ANAVEX ® 2-73 as a potential platform drug for other neurodegenerative diseases

beyond Alzheimer’s disease, Parkinson’s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X

syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex (TSC).

ANAVEX ® 2-73 demonstrated significant

improvements in all of these indications in the respective preclinical animal models.

In a preclinical study sponsored by the Foundation

for Angelman Syndrome, ANAVEX ® 2-73 was assessed in a mouse model for the development of audiogenic seizures.

results indicated that ANAVEX ® 2-73 administration significantly reduced audiogenic-induced seizures in mice.

a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX ® 2-73

restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels.

BDNF under-expression has been observed

in many neurodevelopmental and neurodegenerative pathologies.

BDNF signaling promotes maturation of both excitatory and inhibitory

ANAVEX ® 2-73 normalization of BDNF expression could be a contributing factor for the positive preclinical

data observed in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.

In addition, preclinical data to-date also

indicates that ANAVEX ® 2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes

during pathological conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental

indicated that ANAVEX ® 2-73 administration significantly reduced audiogenic-induced seizures in mice.

In a study sponsored

by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX ® 2-73 restored hippocampal brain-derived

neurotrophic factor (BDNF) expression to normal levels.

BDNF under-expression has been observed in many neurodevelopmental and neurodegenerative

BDNF signaling promotes maturation of both excitatory and inhibitory synapses.

ANAVEX ® 2-73 normalization of

BDNF expression could be a contributing factor for the positive preclinical data observed in both neurodevelopmental and neurodegenerative

disorders like Angelman and Fragile X syndromes.

In addition, preclinical data to-date also indicates

that ANAVEX ® 2-73 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological

conditions, which, if impaired, may play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

In addition, preclinical data on ANAVEX ® 2-73

related to multiple sclerosis indicates that ANAVEX ® 2-73 may promote remyelination in multiple sclerosis disease.

Further, our data also demonstrates that ANAVEX ® 2-73 has the potential to provide protection for oligodendrocytes

(“OL’s”) and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system neurons

in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.

In March 2018, we presented preclinical data

of ANAVEX ® 2-73 in a genetic mouse model of tuberous sclerosis complex (“TSC”).

TSC is a rare genetic

disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures.

preclinical data demonstrated that treatment with ANAVEX ® 2-73 significantly increased survival and reduced seizures

in those mice.

our data also demonstrates that ANAVEX ® 2-73 has the potential to provide protection for oligodendrocytes and oligodendrocyte

precursor cells (“OPCs”), as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation

and maturation in tissue culture.

In March 2018, we presented preclinical data of ANAVEX ® 2-73

in a genetic mouse model of tuberous sclerosis complex (“TSC”).

TSC is a rare genetic disorder characterized by the growth

of numerous benign tumors in many parts of the body with a high incidence of seizures.

The preclinical data demonstrated that treatment

with ANAVEX ® 2-73 significantly increased survival and reduced seizures in those mice.

ANAVEX ® 3-71

ANAVEX ® 3-71 is a clinical drug

candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been shown

to enhance neuroprotection and cognition in Alzheimer’s disease models.

ANAVEX ® 3-71 is an orally available

clinical drug candidate with a novel mechanism of action via SIGMAR1 activation and M1 muscarinic allosteric modulation, which has been

shown to enhance neuroprotection and cognition in Alzheimer’s disease models.

ANAVEX ® 3-71 is a CNS-penetrable potential

disease modifying treatment for cognitive impairments.

We believe it is effective in very small doses against the major Alzheimer’s

hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects

on inflammation and mitochondrial dysfunctions.

ANAVEX ® 3-71 indicates extensive therapeutic advantages in Alzheimer’s

and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation

and M1 muscarinic allosteric modulation.

A preclinical study examined the response of

ANAVEX ® 3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,

amyloid beta pathology and inflammation with the administration of ANAVEX ® 3-71.

In April 2016, the FDA granted Orphan

Drug Designation to ANAVEX ® 3-71 for the treatment of FTD.

We believe it is effective in against the major Alzheimer’s hallmarks in

transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation

and mitochondrial dysfunctions.

ANAVEX ® 3-71 indicates extensive therapeutic advantages in Alzheimer’s and other protein-aggregation-related

diseases given its ability to enhance neuroprotection and cognition via SIGMAR1 activation and M1 muscarinic allosteric modulation.

A preclinical study examined the response of ANAVEX ® 3-71

in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation

with the administration of ANAVEX ® 3-71.

In April 2016, the FDA granted Orphan Drug Designation to ANAVEX ® 3-71

for the treatment of FTD.

During pathological conditions ANAVEX ® 3-71

demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number

of astrocytes.

In neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, synaptogenesis is believed

to be impaired.

Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX ® 3-71

has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if

impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

In July 2020, we commenced the first Phase

1 clinical trial of ANAVEX ® 3-71.

The trial took place in Australia and was a double-blind, randomized, placebo-controlled,

Phase 1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX ® 3-71

demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number of astrocytes.

In neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, synaptogenesis is believed to be impaired.

preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX ® 3-71 has the potential

to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed to

play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

In July 2020, we commenced the first Phase 1 clinical

trial of ANAVEX ® 3-71.

The trial took place in Australia and was a double-blind, randomized, placebo-controlled, Phase

1 trial to evaluate safety and tolerability, and PK of oral escalating doses of ANAVEX ® 3-71

including effects of food and gender in healthy volunteers.

The trial met its primary and

secondary endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, as

more fully described above under Clinical Trials Overview – Frontotemporal Dementia .

on these results, and ANAVEX ® 3-71 pre-clinical profile, the Company intends to advance ANAVEX ® 3-71

into a biomarker-driven clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer’s disease,

evaluating longitudinal effect of treatment with ANAVEX ® 3-71.

We believe the results of this clinical trial and

preclinical study could serve as a basis for advancing into respective registration trials in the U.S.

The trial met its primary and secondary

endpoints of safety, respectively, with no serious adverse events (SAEs) or dose-limiting toxicities observed, as more fully described

above under Clinical Trials Overview – Schizophrenia, Frontotemporal Dementia and Alzheimer’s disease .

Based on these

results, and ANAVEX ® 3-71 pre-clinical profile, the Company intends to advance ANAVEX ® 3-71 into a biomarker-driven

clinical development dementia program for the treatment of schizophrenia, FTD and Alzheimer’s disease, evaluating longitudinal effect

of treatment with ANAVEX ® 3-71.

We believe the results of this clinical trial and preclinical study could serve as a basis

for advancing into respective registration trials in the U.S.

these trials, the ANAVEX ® 3-71-SZ-001 clinical trial, commenced in March 2024 and is more fully described above under

Clinical Trials Overview – Schizophrenia.

ANAVEX ® 1-41

ANAVEX ® 1-41 is a sigma-1 agonist.

Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through

the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.

in animal models, ANAVEX ® 1-41 prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis

(programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.

These activities involve both muscarinic and SIGMAR1 systems through a novel mechanism of action.

Preclinical data presented also indicates that

ANAVEX ® 1-41 has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological

conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of

endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.

In addition, in animal models, ANAVEX ® 1-41

prevented the expression of caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus,

the part of the brain that regulates learning, emotion and memory.

These activities involve both muscarinic and SIGMAR1 systems through

a novel mechanism of action.

Preclinical data presented also indicates that ANAVEX ® 1-41

has the potential to demonstrate protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired,

are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.

ANAVEX ® 1066

1 unchanged sentence

ligand, is designed for the potential treatment of neuropathic and visceral pain.

ANAVEX ® 1066 was tested in two

preclinical models of neuropathic and visceral pain that have been extensively validated in rats.

In the chronic constriction injury

model of neuropathic pain, a single oral administration of ANAVEX ® 1066 dose-dependently restored the nociceptive

threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged.

Efficacy was rapid and remained

significant for two hours.

In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory

agent directly into the colon and a single oral administration of ANAVEX ® 1066 returned the nociceptive threshold

to control levels in a dose-dependent manner.

Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal

transit with ANAVEX ® 1066 and a favorable safety profile in a battery of behavioral measures.

ANAVEX ® 1066 was tested in two preclinical

models of neuropathic and visceral pain that have been extensively validated in rats.

In the chronic constriction injury model of neuropathic

pain, a single oral administration of ANAVEX ® 1066 dose-dependently restored the nociceptive threshold in the affected paw

to normal levels while leaving the contralateral healthy paw unchanged.

Efficacy was rapid and remained significant for two hours.

a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and

a single oral administration of ANAVEX ® 1066 returned the nociceptive threshold to control levels in a dose-dependent manner.

Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX ® 1066 and

a favorable safety profile in a battery of behavioral measures.

ANAVEX ® 1037

ANAVEX ® 1037 is designed for

the treatment of prostate and pancreatic cancer.

It is a low molecular weight, synthetic compound exhibiting high affinity for

SIGMAR1 at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels.

In advanced pre-clinical

studies, this compound revealed antitumor potential.

It has also been shown to selectively kill human cancer cells without affecting

normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models.

Scientific publications highlight

the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines.

Sigma receptors

are highly expressed in different tumor cell types.

Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective

In addition, through tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates

may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other

parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.

ANAVEX ® 1037 is currently in

the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical

models will be shown in human testing.

We continue to identify and initiate discussions

with potential strategic and commercial partners to most effectively advance our programs and increase stockholder value.

we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further

ANAVEX ® 1037 is designed for the treatment

of prostate and pancreatic cancer.

It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at

nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels.

In advanced pre-clinical studies,

this compound revealed antitumor potential.

It has also been shown to selectively kill human cancer cells without affecting normal/healthy

cells and also to significantly suppress tumor growth in immune-deficient mice models.

Scientific publications highlight the possibility

that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines.

Sigma receptors are highly expressed

in different tumor cell types.

Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis.

In addition, through

tumor cell membrane reorganization and interactions with ion channels, we believe our drug candidates may play an important role in inhibiting

the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation

of new blood vessels) and tumor cell proliferation.

ANAVEX ® 1037 is currently in the pre-clinical

and clinical testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown

in human testing.

We continue to identify and initiate discussions with

potential strategic and commercial partners to most effectively advance our programs and increase stockholder value.

Further, we may acquire

or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.

Our Target Indications

We are developing compounds with potential

application to two broad categories and several specific indications, including:

We are developing compounds with potential application

to two broad categories and several specific indications, including:

Central Nervous System Diseases

disease – In 2023, an estimated 6.7 million Americans aged 65 and older are suffering from Alzheimer’s disease.

The Alzheimer’s Association ® estimates that the annual number of new cases of Alzheimer’s and other

dementias is projected to double by 2050.

Medications on the market today treat only the symptoms of Alzheimer’s disease

and do not have the ability to stop its onset or its progression.

We believe that there is an urgent and unmet need for both

a disease-modifying cure for Alzheimer’s disease as well as for better symptomatic treatments.

disease – Parkinson’s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,

and slow, imprecise movement.

It is associated with degeneration of the basal ganglia of the brain and a deficiency of the

neurotransmitter dopamine.

Parkinson’s disease currently is estimated to afflict more than 10 million people worldwide,

typically middle-aged and elderly people.

The Parkinson’s disease market is expected to reach $11.5 billion by 2029,

according to GlobalData.

syndrome – Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way

the brain develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal

It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the

Because males have a different chromosome combination from females, boys who have the genetic MECP2 mutation

are affected in devastating ways.

Alzheimer’s disease – In 2024, an estimated

6.9 million Americans are suffering from Alzheimer’s disease according to the Alzheimer’s Association ® .

Alzheimer’s Association ® estimates that the annual number of new cases of Alzheimer’s and other dementias is

projected to double by 2050.

Medications on the market today treat only the symptoms of Alzheimer’s disease and do not have the

ability to stop its onset or its progression.

We believe that there is an urgent and unmet need for both a disease modifying cure for

Alzheimer’s disease as well as for better symptomatic treatments.

Parkinson’s disease – Parkinson’s

disease is a progressive disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement.

It is associated

with degeneration of the basal ganglia of the brain and deficiency of the neurotransmitter dopamine.

Parkinson’s disease currently

is estimated to afflict more than 10 million people worldwide, typically middle-aged and elderly people.

The Parkinson’s disease

market is expected to reach $11.5 billion by 2029, according to GlobalData.

Rett syndrome – Rett syndrome is a rare X-linked

genetic neurological and developmental disorder that affects the way the brain develops, including protein transcription, which is altered

and as a result leads to severe disruptions in neuronal homeostasis.

It is considered a rare, progressive neurodevelopmental disorder

and is caused by a single mutation in the MECP2 gene.

Because males have a different chromosome combination from females, boys who have

the genetic MECP2 mutation are affected in devastating ways.

Most of them die before birth or in early infancy.

For females who survive infancy,

Rett syndrome leads to severe impairments, affecting nearly every aspect of the child’s life;

For females who survive

infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child’s life;

severe mental retardation,

their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.

Rett syndrome

affects approximately 1 in every 10,000-15,000 females.

neurodevelopmental

presentations

characterized

approximately

1:6,000-8,000

– Depression is a major cause of morbidity worldwide according to the World Health Organization.

The global antidepressant

drug market is projected to reach $21 Billion by 2030 according to Allied Market Research.

Pharmaceutical treatment for depression

has been historically dominated by blockbuster brands.

However, the dominance of the leading brands is waning, largely due

to an increase in the number of approvals for antidepressant drugs.

– Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures.

These seizures

are transient signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain.

According to the

Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million Americans.

Today, epilepsy is often controlled,

but not cured, with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic

Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional

anti-epileptic drugs and second generation anti-epileptic drugs.

Pain – We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in

any part of the body.

Neuralgia is more difficult to treat than some other types of pain because it does not respond well

to normal pain medications.

Special medications have become more specific to neuralgia and typically fall under the category

of membrane stabilizing drugs or antidepressants.

Melanoma – Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the

Rett syndrome affects approximately

1 in every 10,000-15,000 females.

Schizophrenia - Schizophrenia is a persistent and

often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including

2.8 million people in the U.S., according to the World Health Organization.

It is characterized by three symptom domains:

positive symptoms

(hallucinations and delusions), negative symptoms (difficulty enjoying life and withdrawal from others), and cognitive impairment (deficits

in memory, concentration, and decision-making).

In part due to limitations with current treatments, people living with schizophrenia often

struggle to maintain employment, live independently, and manage relationships.

While current treatments can be effective in managing select

symptoms, approximately 34% of people do not respond to therapy, with an additional 50-60% experiencing only a partial improvement in

symptoms or unacceptable side effects.

Fragile X – Fragile X syndrome (FXS) is

the most prevalent genetic form of intellectual disability and autism spectrum disorder, primarily affecting boys.

As with most neurodevelopmental

disorders, FXS is considered a condition of synaptic development and function.

The disease has a range of clinical presentations depending

on the specific genetic changes associated with an “expansion” of the FMR1 gene.

The disease is characterized by deficits

in long-term potentiation and homeostatic plasticity.

FXS has been detected in all populations and ethnic groups.

Researchers do not

know the exact number for how many Americans could have full mutation FXS.

Studies estimate that the disease affects approximately 1:4,000

males and 1:6,000 females.

Worldwide, more than 1,400,000 people could be affected by FXS.

Depression – Depression is a major cause of

morbidity worldwide according to the World Health Organization.

The global antidepressant drug market is projected to reach $21 billion

by 2030 according to Allied Market Research.

Pharmaceutical treatment for depression has been historically dominated by blockbuster brands.

However, the dominance of the leading brands is waning, largely due to an increase in the number of approvals for antidepressant drugs.

Epilepsy – Epilepsy is a common chronic neurological

disorder characterized by recurrent unprovoked seizures.

These seizures are transient signs and/or symptoms of abnormal, excessive or

synchronous neuronal activity in the brain.

According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4

million Americans.

Today, epilepsy is often controlled, but not cured, with medications that are categorized as older traditional anti-epileptic

drugs and second-generation anti-epileptic drugs.

Because epilepsy afflicts sufferers in different ways, there is a need for drugs used

in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.

Neuropathic Pain – We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body.

Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal pain medications.

Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.

Malignant Melanoma – Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye.

Malignant melanoma accounts for a large majority of skin cancer deaths.

The treatment includes surgical removal of the

tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.

The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.

According to iHealthcareAnalyst, Inc.

the worldwide

malignant melanoma market is expected to grow to $7.5 billion by 2029.

Cancer – Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive

the worldwide malignant melanoma market is expected to grow to $7.5 billion by 2029.

Prostate Cancer – Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system.

Cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.

Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market

Research Future.

Cancer – Pancreatic cancer is a malignant neoplasm of the pancreas.

In the United States, approximately 62,000 new cases

of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according

to the American Cancer Society.

Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical

treatment of pancreatic cancer will increase to $3.7 billion by 2027.

The drug discovery and development industry

is very competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential.

Any product candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies

that may become available in the future.

Our commercial opportunities could be reduced or eliminated if our competitors develop

and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any

products that we may develop.

We believe our approach to the treatment

of Alzheimer’s disease and other CNS diseases differs from our competitors - our platform may offer a disease-modifying approach

in neurodegenerative and neurodevelopmental diseases by activation of SIGMAR1.

In our preclinical studies, when activated by SIGMAR1

agonists, such as ANAVEX ® 2-73, SIGMAR1 demonstrated reduced cellular stress before and after RNA gene transcription.

Our studies confirm the potential existence of a predictive biomarker of response established through SIGMAR1 mRNA expression that

could be used in future clinical trials.

Because of its role in maintaining neuronal homeostasis, we believe sigma receptors show

significant promise as viable targets for therapeutic molecules in an effort to treat Alzheimer’s disease and other CNS diseases

and disorders, including Parkinson’s disease and Rett syndrome, by restoring healthy gene expression.

At this time, our competitors are primarily

other biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer’s

disease and other CNS diseases, and those companies already doing so.

We also face competition from academic institutions and government

agencies, both in the United States and abroad.

Our competitors may have significantly

greater financial resources, an established presence in the market, expertise in research and development, manufacturing, preclinical

and clinical testing, may be in the process of obtaining regulatory approvals and marketing of approved products.

These competitors

also compete with us in recruiting and retaining qualified scientific and technical personnel, establishing clinical trial sites

and patient registration for clinical trials, as well as in acquiring or developing technologies complementary to, or necessary

for, our programs.

Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative

arrangements with large and established companies.

For additional discussion of the risks

related to competition, see Item 1A “Risk Factors.”

Patents, Trademarks and Intellectual

We hold ownership or exclusive rights to twenty-two

patents, twenty-three U.S.

Drug therapeutics for prostate cancer are expected to increase to nearly $10.1 billion by the end of 2030 according to Market Research Future.

Pancreatic Cancer – Pancreatic cancer is a malignant neoplasm of the pancreas.

In the United States, approximately 62,000 new cases of pancreatic cancer will be diagnosed this year and approximately 50,000 patients will die as a result of their cancer, according to the American Cancer Society.

Sales predictions by Market Data Forecast predict that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $3.7 billion by 2027.

The drug discovery and development industry is very

competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential.

candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies that may become available

in the future.

Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that

are more effective, have fewer side effects, are more convenient or are less expensive than any products that we may develop.

We believe our approach to the treatment of Alzheimer’s

disease and other CNS diseases differs from our competitors.

Our platform may offer a disease-modifying approach in neurodegenerative

and neurodevelopmental diseases by activation of SIGMAR1.

In our preclinical studies, when activated by SIGMAR1 agonists, such as ANAVEX ® 2-73,

SIGMAR1 demonstrated reduced cellular stress before and after RNA gene transcription.

Our studies confirm the potential existence of a

predictive biomarker of response established through SIGMAR1 mRNA expression that could be used in future clinical trials.

its role in maintaining neuronal homeostasis, we believe sigma receptors show significant promise as viable targets for therapeutic molecules

in an effort to treat Alzheimer’s disease and other CNS diseases and disorders, including Parkinson’s disease and Rett syndrome,

by restoring healthy gene expression.

At this time, our competitors are primarily other

biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer’s disease

and other CNS diseases, and those companies already doing so.

We also face competition from academic institutions and government agencies,

both in the United States and abroad.

Our competitors may have significantly greater financial

resources, an established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing,

may be in the process of obtaining regulatory approvals and marketing of approved products.

These competitors also compete with us in

recruiting and retaining qualified scientific and technical personnel, establishing clinical trial sites and patient registration for

clinical trials, as well as in acquiring or developing technologies complementary to, or necessary for, our programs.

Smaller or early-stage

companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

For additional discussion of the risks related to

competition, see Item 1A “Risk Factors.”

Patents, Trademarks and Intellectual Property

We hold ownership or exclusive rights to twenty-five

patents, twenty-five (25) U.S.

patent applications, and various PCT or ex-U.S.

3 unchanged sentences

patent entitled “ANAVEX ® 2-73

and certain anticholinesterase inhibitors composition and method for neuroprotection” claims a composition of matter of ANAVEX ® 2-73

and certain anticholinesterase inhibitors composition and method for neuroprotection,” which claims a composition of matter of ANAVEX ® 2-73

directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors.

patent is expected to expire in June 2034, absent any patent term extension for regulatory delays.

is expected to expire in June 2034, absent any patent term extension for regulatory delays.

We own one issued U.S.

entitled “A2-73 crystalline polymorph compositions of matter and methods of use thereof”.

It claims crystals of A2-73

freebase or its fumarate salt, dosage forms and pharmaceutical formulations.

This patent is expected to expire in July 2039, absent

any patent term extension for regulatory delays.

patent entitled “A2-73

crystalline polymorph compositions of matter and methods of use thereof”.

It claims crystals of A2-73 freebase or its fumarate salt,

dosage forms and pharmaceutical formulations.

This patent is expected to expire in July 2039, absent any patent term extension for regulatory

We own four issued U.S.

patents each with claims directed to crystalline forms

of ANAVEX ® 2-73.

The first of these four patents claims crystalline forms of ANAVEX ® 2-73, dosage forms

and compositions containing crystalline ANAVEX ® 2-73, and methods of treatment for Alzheimer’s disease using

patents each with claims directed

to crystalline forms of ANAVEX ® 2-73.

The first of these four patents claims crystalline forms of ANAVEX ® 2-73,

dosage forms and compositions containing crystalline ANAVEX ® 2-73, and methods of treatment for Alzheimer’s disease

This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays.

3 unchanged sentences

This patent is expected to expire in June 2036, absent any patent term extension

regulatory delays.

for regulatory delays.

The third of these four patents claims pharmaceutical compositions containing a crystalline form of ANAVEX ® 2-73,

and methods of treatment for Alzheimer’s disease using the compositions.

This patent is expected to expire in June 2036,

absent any patent term extension for regulatory delays.

The fourth of these four patents claims method of making certain crystalline

forms ANAVEX ® 2-73.

This patent is expected to expire in October 2036, absent any patent term extension for regulatory

We also own three issued U.S.

patents for seizure treatment.

The first of these three patents claims methods and dosage

forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either:

(i) ANAVEX ® 2-73

and its active metabolite ANAVEX ® 19-144;

or (ii) ANAVEX ® 19-144.

The second of these three patents

further claims a combination seizure treatment involving administration of an anti-epilepsy drug combined with (i) ANAVEX ® 19-144,

or (ii) ANAVEX 19-144 ® and ANAVEX 2-73 ® .

The third of these three patents claims a dosage form for

seizure reduction, comprising (i) ANAVEX19-144 ® , (ii) ANAVEX 2-73 ® , or (iii) a combination of ANAVEX19-144 ®

and ANAVEX 2-73 ® ;

and optionally further comprising a low-dose anti-epilepsy drug.

All three patents are

expected to expire in October 2035, absent any patent term extension for regulatory delays.

This patent is expected to expire in June 2036, absent

any patent term extension for regulatory delays.

The fourth of these four patents claims method of making certain crystalline forms ANAVEX ® 2-73.

This patent is expected to expire in October 2036, absent any patent term extension for regulatory delays.

We also own three issued U.S.

with claims directed to treating neurodevelopmental disorders.

These patents claim methods for treating a neurodevelopmental disorder,

multiple sclerosis, or their related biochemical and functional abnormalities by administering ANAVEX ® 2-73, ANAVEX ® 19-144,

and/or ANAVEX ® 1-41 (another sigma receptor ligand similar to ANAVEX ® 2-73), or compositions thereof.

All three patents are expected to expire in January 2037, absent any patent term extension for regulatory delays.

we own one issued U.S.

Patent with claims directed to methods of treating melanoma with a compound related to ANAVEX ® 2-73.

This patent is expected to expire in February 2030, absent any patent term extension for regulatory delays.

We also own an issued

patent that claims crystalline forms of ANAVEX ® 19-144, dosage forms and compositions containing the crystalline

forms of ANAVEX ® 19-144, and methods of treatment for Alzheimer’s disease.

This patent is expected to expire

in July 2036, absent any patent term extension for regulatory delays.

patents for seizure

The first of these three patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose

anti-epilepsy drug combined with either:

(i) ANAVEX ® 2-73 and its active metabolite ANAVEX ® 19-144;

ANAVEX ® 19-144.

The second of these three patents further claims a combination seizure treatment involving administration

of an anti-epilepsy drug combined with (i) ANAVEX ® 19-144, or (ii) ANAVEX ® 19-144 and ANAVEX ® 2-73.

The third of these three patents claims a dosage form for seizure reduction, comprising (i) ANAVEX ® 19-144, (ii) ANAVEX ® 2-73,

or (iii) a combination of ANAVEX ® 19-144 and ANAVEX ® 2-73;

and optionally further comprising a low-dose anti-epilepsy

All three patents are expected to expire in October 2035, absent any patent term extension for regulatory delays.

We also own four issued U.S.

patents with claims directed

to treating neurodevelopmental disorders.

These patents claim methods for treating a neurodevelopmental disorder, multiple sclerosis,

their related biochemical and functional abnormalities, or loss-of-function associated with a neurodevelopmental disorder, by administering

ANAVEX ® 2-73, ANAVEX ® 19-144, and/or ANAVEX ® 1-41 (another sigma receptor ligand similar to

ANAVEX ® 2-73), or compositions thereof.

All four patents are expected to expire in January 2037, absent any patent term

extension for regulatory delays.

In addition, we own one issued U.S.

patent with claims

directed to methods of treating melanoma with a compound related to ANAVEX ® 2-73.

This patent is expected to expire in February

2030, absent any patent term extension for regulatory delays.

We also own an issued U.S.

patent that claims crystalline

forms of ANAVEX ® 19-144, dosage forms and compositions containing the crystalline forms of ANAVEX ® 19-144,

and methods of treatment for Alzheimer’s disease.

This patent is expected to expire in July 2036, absent any patent term extension

for regulatory delays.

Further, we own one issued U.S.

Patent with claims directed

to methods of treating cardiac dysfunction with ANAVEX ® 2-73.

patent with claims

directed to methods of treating cardiac dysfunction with ANAVEX ® 2-73.

This patent is expected to expire in July 2038, absent

any patent term extension for regulatory delays.

Additionally, we own one issued U.S.

Patent with claims directed to methods of

treating insomnia or anxiety with ANAVEX ® 2-73, ANAVEX ® 19-144, and/or ANAVEX ® 1-41.

This patent is expected to expire in September 2038, absent any patent term extension for regulatory delays.

Further, we own one

Patent with claims directed to a method of treating systolic hypertension using ANAVEX ® 2-73.

is expected to expire in July 2039, absent any patent term extension for regulatory delays.

Additionally, we own two issued U.S.

patent for the treatment of insomnia, anxiety, or

The first of the two patents claims methods of treating insomnia or anxiety with ANAVEX ® 2-73, ANAVEX ® 19-144,

and/or ANAVEX ® 1-41.

This patent is expected to expire in September 2038.

The second of the two patents claims a dosage

form comprising any of, or any combination of ANAVEX ® 2-73, ANAVEX ® 19-144, and/or ANAVEX ® 1-41.

This patent is expected to expire in July 2038, absent any patent term extension for regulatory delays.

Further, we own one issued U.S.

patent with claims

directed to a method of treating systolic hypertension using ANAVEX ® 2-73.

This patent is expected to expire in July 2039,

absent any patent term extension for regulatory delays.

Additionally, we own one issued U.S.

Patent with claims directed to pharmaceutical dosage forms of (-) enantiomer of ANAVEX ® 2-73.

This patent is expected

to expire in July 2036, absent any patent term extension for regulatory delays.

We also own two issued U.S.

patent with claims directed to pharmaceutical

dosage forms of (-) enantiomer of ANAVEX ® 2-73.

This patent is expected to expire in July 2036, absent any patent term extension

for regulatory delays.

We also own three (3) issued U.S.

patents related

to ANAVEX ® 1066.

The first of these two patents claims methods for treating or preventing pain using (+) ANAVEX ® 1066

The first of these three patents claims methods for treating or preventing pain using (+) ANAVEX ® 1066

The second patent claims methods for treating or preventing pain using (-) ANAVEX ® 1066 isomer.

are expected to expire in November 2036, absent any patent term extension for regulatory delays.

The third patent

claims dosage forms and pharmaceutical compositions comprising (+) ANAVEX ® 1066 isomer.

All three patents are expected to

expire in November 2036, absent any patent term extension for regulatory delays.

For ANAVEX ® 2-73, ANAVEX ® 19-144,

ANAVEX ® 1-41, and ANAVEX ® 1066, we also have granted or pending applications in Australia, Canada,

China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.

With regard to ANAVEX ® 3-71,

we own exclusive rights to two issued U.S.

patents with claims respectively directed to the ANAVEX ® 3-71 compound

and methods of treating various diseases including Alzheimer’s with the same.

These patents are expected to expire in April

2030, and January 2030, respectively, absent any patent term extension for regulatory delays.

We also own exclusive rights to related

patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and

South Africa, which are expected to expire in January 2030.

We also own other patent applications directed

to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for one or more

of our product candidates.

ANAVEX ® 1-41, and ANAVEX ® 1066, we also have granted or pending applications in Australia, Canada, China,

Europe, Japan, and Hong Kong, which are expected to expire after 2035.

With regard to ANAVEX ® 3-71, we own

exclusive rights to two issued U.S.

patents with claims respectively directed to the ANAVEX ® 3-71 compound and methods of

treating various diseases including Alzheimer’s with the same.

These patents are expected to expire in April 2030, and January 2030,

respectively, absent any patent term extension for regulatory delays.

We also own exclusive rights to related patents or applications

that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and South Africa, which are expected

to expire in January 2030.

We also own other patent applications and certain

granted foreign patents directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional

protection for one or more of our product candidates.

We regard patents and other intellectual property

2 unchanged sentences

including the selective development, protection, and exploitation of our intellectual property rights.

In addition to filings made

with intellectual property authorities, we protect our intellectual property and confidential information by means of carefully

considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements

and provisions for the same in contractor’s agreements.

While no agreement offers absolute protection, such agreements provide

some form of recourse in the event of disclosure, or anticipated disclosure.

In addition to filings made with

intellectual property authorities, we protect our intellectual property and confidential information by means of carefully considered

processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure agreements and provisions

for the same in contractor’s agreements.

While no agreement offers absolute protection, such agreements provide some form of recourse

in the event of disclosure, or anticipated disclosure.

intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions

for which important legal principles are unresolved.

For more information regarding challenges to our existing or future patents,

see “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.

For more information regarding challenges to our existing or future patents, see

“Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.

Government regulation

Government authorities in the United States,

at the federal, state and local levels, and other countries extensively regulate, among other things, the research, development,

testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,

marketing and export and import of products such as those we are developing.

A new drug must be approved by the FDA through the

NDA or ANDA process before it may be legally marketed in the United States.

We are subject to various government regulations in

connection with the development of our pipeline.

Government authorities in the United States, at the

federal, state and local levels, and other countries extensively regulate, among other things, the research, development, testing, manufacture,

quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and

import of products such as those we are developing.

A new drug must be approved by the FDA through the NDA or ANDA process before it may

be legally marketed in the United States.

We are subject to various government regulations in connection with the development of our pipeline.

Drug Development and Regulation

In the United States, the FDA regulates drugs

under the Federal Food, Drug, and Cosmetic Act and its implementing regulations (“FDCA”).

The process of obtaining

regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations

require the expenditure of substantial time and financial resources.

In the United States, the FDA regulates drugs under

the Federal Food, Drug, and Cosmetic Act and its implementing regulations (“FDCA”).

The process of obtaining regulatory approvals

and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial

time and financial resources.

Failure to comply with the applicable U.S.

requirements at

any time during the product development process, approval process or post approval may subject an applicant to administrative or

judicial sanctions.

These sanctions could include the FDA’s refusal to approve pending applications, withdrawal of an approval,

import refusal, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production

or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.

Any agency or judicial enforcement action could have a material adverse effect on us.

requirements at any time during the product development process,

approval process or post approval may subject an applicant to administrative or judicial sanctions.

These sanctions could include the

FDA’s refusal to approve pending applications, withdrawal of an approval, import refusal, a clinical hold, warning letters, product

recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,

restitution, disgorgement or civil or criminal penalties.

Any agency or judicial enforcement action could have a material adverse effect

Once a drug candidate is identified for development,

1 unchanged sentence

development of the product.

Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as

well as other preclinical studies.

An IND sponsor must submit the results of the preclinical tests, together with manufacturing

information and analytical data, to the FDA as part of the IND to conduct clinical trials.

The sponsor must also include a protocol

detailing, among other things, the objectives of the clinical trials, the parameters to be used in monitoring the safety of the

trial, and the effectiveness criteria to be evaluated should the trial include an efficacy evaluation.

Some preclinical testing

may continue even after the IND is filed.

The IND automatically becomes effective thirty (30) days after receipt by the FDA, unless

the FDA, within the 30-day time period, places the clinical trial on a clinical hold.

Clinical holds also may be imposed by the

FDA at any time before or during clinical trials due to safety concerns about ongoing or proposed clinical trials or non-compliance

with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been

All clinical trials must be conducted under

the supervision of one or more qualified investigators in accordance with FDA good clinical practice (“GCP”) requirements,

which include a requirement that all research subjects provide their informed consent in writing for their participation in any

clinical trial.

Clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject

selection inclusion and exclusion criteria and the safety and/or effectiveness criteria to be evaluated.

Each protocol must be

submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious

and unexpected adverse events.

An Institutional Review Board (“IRB”) at each institution participating in the clinical

trial must review and approve each protocol before a clinical trial may commence at the institution and must also approve the information

regarding the trial as well as the informed consent form that must be provided to each trial participant or his or her legal representative,

monitor the study until completed and otherwise comply with all applicable IRB regulations.

Human clinical trials are typically conducted

in three sequential phases that may overlap or be combined in certain cases:

The compound is initially introduced

into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if

possible, to gain an early indication of its effectiveness.

In most cases, initial Phase 1 clinical trials are conducted with healthy

However, where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer,

and especially when the product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be

conducted on patients with the target disease or condition.

Sponsors sometimes subdivide their Phase 1 clinical trials into Phase

1a and Phase 1b clinical trials.

Phase 1b clinical trials are typically aimed at confirming dosage, PK and safety in a larger number

Some Phase 1b clinical trials evaluate biomarkers or surrogate markers that may be associated with efficacy in patients

with specific types of diseases or conditions.

This phase involves clinical trials

in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of

the product for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.

Phase 3 clinical trials are undertaken

to further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed

clinical trial sites.

These clinical trials, often referred to as “pivotal” or “confirmatory” clinical

trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis

for product approval and labeling.

The FDA or the sponsor may suspend a clinical

trial at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable

Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is

not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected, serious

harm to study subjects.

In addition, clinical trials may be overseen by an independent group of qualified experts organized by

the sponsor, known as a data safety monitoring board or committee.

Depending on its charter, this board or committee may determine

whether a trial may move forward at designated check points based on access to certain data from the trial.

Phase 4 or post-approval trials may

also be conducted after a drug receives initial marketing approval.

These trials, often referred to as “Phase 4” trials,

are used to gain additional experience from the treatment of patients in the intended therapeutic indication.

In certain instances,

the FDA may mandate the performance of such clinical trials as a condition of approval of continued marketing of the product.

During the development of a new drug, sponsors

are given several opportunities to meet with the FDA.

These meetings can provide an opportunity for the sponsor to share information

about the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach

agreement on the next phase of development.

These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical

trials, or before an NDA is ultimately submitted.

Sponsors typically use the meetings at the end of the Phase 2 trials to discuss

Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the

Meetings at other times may be made upon request and are subject to approval by the FDA.

Concurrent with clinical trials, companies

typically complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physicochemical

characteristics of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the

FDA’s current Good Manufacturing Practices (“cGMP”) requirements.

The manufacturing process must consistently

produce quality batches of the drug and, among other things, the manufacturer must develop methods for testing the identity, strength,

quality and purity of the final drug.

In addition, appropriate packaging must be selected and tested, and stability studies must

be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration

over its shelf life.

Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as

other preclinical studies.

An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and

analytical data, to the FDA as part of the IND to conduct clinical trials.

The sponsor must also include a protocol detailing, among other

things, the objectives of the clinical trials, the parameters to be used in monitoring the safety of the trial, and the effectiveness

criteria to be evaluated should the trial include an efficacy evaluation.

Some preclinical testing may continue even after the IND is

The IND automatically becomes effective thirty (30) days after receipt by the FDA, unless the FDA, within the 30-day time period,

places the clinical trial on a clinical hold.

Clinical holds also may be imposed by the FDA at any time before or during clinical trials

due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may

not begin or continue until the FDA notifies the sponsor that the hold has been lifted.

All clinical trials must be conducted under the supervision

of one or more qualified investigators in accordance with FDA good clinical practice (“GCP”) requirements, which include a

requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial.

trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection inclusion and exclusion

criteria and the safety and/or effectiveness criteria to be evaluated.

Each protocol must be submitted to the FDA as part of the IND,

and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events.

An Institutional

Review Board (“IRB”) at each institution participating in the clinical trial must review and approve each protocol before

a clinical trial may commence at the institution and must also approve the information regarding the trial as well as the informed consent

form that must be provided to each trial participant or his or her legal representative, monitor the study until completed and otherwise

comply with all applicable IRB regulations.

Human clinical trials are typically conducted in three

sequential phases that may overlap or be combined in certain cases:

The compound is initially introduced into

healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to

gain an early indication of its effectiveness.

In most cases, initial Phase 1 clinical trials are conducted with healthy volunteers.

where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer, and especially when the

product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be conducted on patients with the

target disease or condition.

Sponsors sometimes subdivide their Phase 1 clinical trials into Phase 1a and Phase 1b clinical trials.

1b clinical trials are typically aimed at confirming dosage, PK and safety in a larger number of patients.

Some Phase 1b clinical trials

evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases or conditions.

This phase involves clinical trials in a

limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product

for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.

Phase 3 clinical trials are undertaken to

further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed clinical

These clinical trials, often referred to as “pivotal” or “confirmatory” clinical trials, are intended

to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis for product approval and labeling.

The FDA or the sponsor may suspend a clinical trial

at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable health

Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted

in accordance with the IRB’s requirements or if the drug has been associated with unexpected, serious harm to study subjects.

addition, clinical trials may be overseen by an independent group of qualified experts organized by the sponsor, known as a data safety

monitoring board or committee.

Depending on its charter, this board or committee may determine whether a trial may move forward at designated

check points based on access to certain data from the trial.

Phase 4 or post-approval trials may also

be conducted after a drug receives initial marketing approval.

These trials, often referred to as “Phase 4” trials, are used

to gain additional experience from the treatment of patients in the intended therapeutic indication.

In certain instances, the FDA may

mandate the performance of such clinical trials as a condition of approval of continued marketing of the product.

During the development of a new drug, sponsors are

given several opportunities to meet with the FDA.

These meetings can provide an opportunity for the sponsor to share information about

the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement

on the next phase of development.

These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical trials, or

before an NDA is ultimately submitted.

Sponsors typically use the meetings at the end of the Phase 2 trials to discuss Phase 2 clinical

results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.

other times may be made upon request and are subject to approval by the FDA.

Concurrent with clinical trials, companies typically

complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physicochemical characteristics

of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the FDA’s current

Good Manufacturing Practices (“cGMP”) requirements.

The manufacturing process must consistently produce quality batches of

the drug and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the

In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the

effectiveness of the packaging and that the compound does not undergo unacceptable deterioration over its shelf life.

While the IND is active, progress reports summarizing

the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at

least an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and

unexpected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs,

findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence

of a serious adverse reaction compared to that listed in the protocol or investigator brochure.

the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at least

an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected adverse

events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal

or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence of a serious adverse reaction

compared to that listed in the protocol or investigator brochure.

There are also requirements governing the submission

of certain clinical trials and completed trial results to public registries.

Sponsors of certain clinical trials of FDA-regulated

products are required to register and disclose specified clinical trial registration and results information, which is made publicly

available at www.clinicaltrials.gov.

Sponsors of certain clinical trials of FDA-regulated products

are required to register and disclose specified clinical trial registration and results information, which is made publicly available

at www.clinicaltrials.gov.

Failure to properly report clinical trial results can result in civil monetary penalties.

Disclosure of clinical trial results can often be delayed until the new product or new indication being studied has been approved.

Disclosure of clinical

trial results can often be delayed until the new product or new indication being studied has been approved.

review and approval process

The results of product development, preclinical

and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted

on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application

The results of product development, preclinical and

other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the

chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application (“NDA”).

The submission of an NDA is subject to the payment of substantial user fees;

a waiver of which may be obtained

under certain limited circumstances.

The FDA reviews NDAs to determine, among other

things, whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner,

which will assure and preserve the product’s identity, strength, quality and purity.

Under the Prescription Drug User Fee

Act (“PDUFA”), the FDA has a goal of ten months from the date of “filing” of a standard, completed NDA

for a new molecular entity to review and act on the submission.

This review typically takes twelve months from the date the NDA

is submitted to the FDA because the FDA has approximately two months to make a “filing” decision after the application

is submitted.

The FDA conducts a preliminary review of all NDAs within the first sixty days after submission, before accepting

them for filing, to determine whether they are sufficiently complete to permit substantive review.

The FDA may request additional

information rather than accept an NDA for filing.

In this event, the NDA must be resubmitted with the additional information.

resubmitted application also is subject to review before the FDA accepts it for filing.

The FDA may refer an application for a new

drug to an advisory committee.

An advisory committee is a panel of independent experts, including clinicians and other scientific

experts, that reviews, evaluates and provides a recommendation as to whether and under what conditions the application should be

The FDA is not bound by the recommendations of such an advisory committee, but it considers advisory committee recommendations

carefully when making decisions.

Before approving an NDA, the FDA will also

inspect the facility where the product is manufactured.

The FDA will not approve an application unless it determines that the manufacturing

processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product

within required specifications.

Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance

with GCP requirements and inspect the clinical trial records.

After the FDA evaluates an NDA, it will issue

an approval letter or a Complete Response Letter.

A Complete Response Letter indicates that the review cycle of the application

is complete, and the application will not be approved in its present form.

A Complete Response Letter usually describes the specific

deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial

or other significant and time-consuming requirements related to clinical trials, nonclinical studies or product manufacturing.

If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the

letter, or withdraw the application.

Even if such data and information are submitted, the FDA may decide that the NDA does not

satisfy the criteria for approval.

An approval letter authorizes commercial marketing of the drug with prescribing information

for specific indications.

a waiver of which may be obtained under certain limited circumstances.

The FDA reviews NDAs to determine, among other things,

whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner, which will assure

and preserve the product’s identity, strength, quality and purity.

Under the Prescription Drug User Fee Act (“PDUFA”),

the FDA has a goal of ten months from the date of “filing” of a standard, completed NDA for a new molecular entity to review

and act on the submission.

This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has

approximately two months to make a “filing” decision after the application is submitted.

The FDA conducts a preliminary review

of all NDAs within the first sixty days after submission, before accepting them for filing, to determine whether they are sufficiently

complete to permit substantive review.

The FDA may request additional information rather than accept an NDA for filing.

In this event,

the NDA must be resubmitted with the additional information.

The resubmitted application also is subject to review before the FDA accepts

it for filing.

The FDA may refer an application for a new drug to

an advisory committee.

An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that

reviews, evaluates and provides a recommendation as to whether and under what conditions the application should be approved.

not bound by the recommendations of such an advisory committee, but it considers advisory committee recommendations carefully when making

Before approving an NDA, the FDA will also inspect

the facility where the product is manufactured.

The FDA will not approve an application unless it determines that the manufacturing processes

and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required

specifications.

Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance with GCP requirements

and inspect the clinical trial records.

After the FDA evaluates an NDA, it will issue an approval

letter or a Complete Response Letter.

A Complete Response Letter indicates that the review cycle of the application is complete, and the

application will not be approved in its present form.

A Complete Response Letter usually describes the specific deficiencies in the NDA

identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming

requirements related to clinical trials, nonclinical studies or product manufacturing.

If a Complete Response Letter is issued, the sponsor

must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application.

Even if such data and

information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.

An approval letter authorizes commercial

marketing of the drug with prescribing information for specific indications.

The Pediatric Research Equity Act (“PREA”),

requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage

form, new dosing regimen or new route of administration.

Under PREA, original NDAs and supplements must contain a pediatric assessment

unless the sponsor has received a deferral or waiver.

The required assessment must evaluate the safety and effectiveness of the

product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric

subpopulation for which the product is safe and effective.

The sponsor or the FDA may request a deferral of pediatric clinical

trials for some or all of the pediatric subpopulations.

A deferral may be granted for several reasons, including a finding that

the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness

data needs to be collected before the pediatric clinical trials begin.

The FDA must send a non-compliance letter to any sponsor

that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric

If a drug receives FDA approval, the approval

may be limited to specific diseases and dosages, which could restrict the commercial value of the product.

In addition, the FDA

may require testing and surveillance programs to monitor the safety of approved products which have been commercialized and may

require a sponsor to conduct post-marketing clinical trials (Phase 4 clinical trials), which are designed to further assess a drug’s

safety and effectiveness after NDA approval.

The FDA may also place other conditions on approval, including a requirement for a

risk evaluation and mitigation strategy (“REMS”) to assure the safe use of the drug.

If the FDA concludes a REMS is

needed, the sponsor of the NDA must submit a proposed REMS.

requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form,

new dosing regimen or new route of administration.

Under PREA, original NDAs and supplements must contain a pediatric assessment unless

the sponsor has received a deferral or waiver.

The required assessment must evaluate the safety and effectiveness of the product for the

claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for

which the product is safe and effective.

The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of

the pediatric subpopulations.

A deferral may be granted for several reasons, including a finding that the drug is ready for approval for

use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before

the pediatric clinical trials begin.

The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment,

keep a deferral current or fails to submit a request for approval of a pediatric formulation.

If a drug receives FDA approval, the approval may

be limited to specific diseases and dosages, which could restrict the commercial value of the product.

In addition, the FDA may require

testing and surveillance programs to monitor the safety of approved products which have been commercialized and may require a sponsor

to conduct post-marketing clinical trials (Phase 4 clinical trials), which are designed to further assess a drug’s safety and effectiveness

after NDA approval.

The FDA may also place other conditions on approval, including a requirement for a risk evaluation and mitigation

strategy (“REMS”) to assure the safe use of the drug.

If the FDA concludes a REMS is needed, the sponsor of the NDA must submit

a proposed REMS.

The FDA will not approve the NDA without an approved REMS, if required.

A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution

methods, patient registries and other risk minimization tools.

Any of these limitations on approval or marketing could restrict

the commercial promotion, distribution, prescribing or dispensing of products.

Marketing approval may be withdrawn for non-compliance

with REMS or other regulatory requirements, or if problems occur following initial marketing.

A REMS could include medication guides, physician

communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization

Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescribing or dispensing

Marketing approval may be withdrawn for non-compliance with REMS or other regulatory requirements, or if problems occur following

initial marketing.

Post-approval requirements

1 unchanged sentence

the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market.

Later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of

the drug from the market.

After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing

changes and additional labeling claims, are subject to further FDA review and approval.

Manufacturers and other entities involved

in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state

agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations

and other laws and regulations.

Any drug product manufactured or distributed

by us pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping

requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug

sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with

FDA promotion and advertising requirements.

FDA strictly regulates labeling, advertising, promotion and other types of information

regarding approved drugs that are placed on the market, and imposes requirements and restrictions on drug manufacturers, such as

those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that

are not described in the product’s approved labeling (known as “off-label use”), industry-sponsored scientific

and educational activities, and promotional activities involving the internet.

Discovery of previously unknown problems or the

failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product for a certain

indication or withdrawal of the product from the market as well as possible civil or criminal sanctions.

Failure to comply with

the applicable governmental requirements at any time during the product development process, approval process or after approval,

may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity.

sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing clinical

trials, enforcement letters, import refusals, product recalls, product seizures, total or partial suspension of production or distribution,

injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,

Later discovery

of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of the drug from the market.

After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing changes and additional

labeling claims, are subject to further FDA review and approval.

Manufacturers and other entities involved in the manufacture and distribution

of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced

inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations.

Any drug product manufactured or distributed by us

pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,

reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution

requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements.

FDA strictly regulates labeling, advertising, promotion and other types of information regarding approved drugs that are placed on the

market, and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the

prohibition on promoting products for uses or in patient populations that are not described in the product’s approved labeling (known

as “off-label use”), industry-sponsored scientific and educational activities, and promotional activities involving the internet.

Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions

on the marketing of a product for a certain indication or withdrawal of the product from the market as well as possible civil or criminal

Failure to comply with the applicable governmental requirements at any time during the product development process, approval

process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse

The FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing

clinical trials, enforcement letters, import refusals, product recalls, product seizures, total or partial suspension of production or

distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,

restitution, disgorgement of profits, or civil or criminal penalties.

Expedited development and review programs

The FDA has a fast track designation program

that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria.

Specifically,

new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition

and demonstrate the potential to address unmet medical needs for the disease or condition.

With regard to a fast track product,

the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor

provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines

that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

Any product submitted to the FDA for approval,

including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development

and review, such as priority review and accelerated approval.

A product is eligible for priority review if

it is intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared

to currently marketed products.

The FDA will attempt to direct additional resources to the evaluation of an application for a new

drug designated for priority review in an effort to facilitate the review.

The FDA endeavors to review applications with priority

review designations within six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA

review goals.

In addition, a product may be eligible for

accelerated approval.

Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated

approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical

benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely

to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,

or prevalence of the condition and the availability or lack of alternative treatments.

As a condition of approval, the FDA may

require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials.

Drugs receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required

post-marketing trials or if such trials fail to verify the predicted clinical benefit.

In addition, the FDA currently requires

as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial

launch of the product.

The Food and Drug Administration Safety and

Innovation Act (“FDASIA”) established a category of drugs referred to as “breakthrough therapies” that

may be eligible to receive breakthrough therapy designation.

A sponsor may seek FDA designation of a compound as a “breakthrough

therapy” if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening

disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over

existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical

The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance.

The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be

granted to the same drug if relevant criteria are met.

If a product is designated as breakthrough therapy, the FDA will work to

expedite the development and review of such drug.

Fast track designation, priority review and

breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.

However, even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets

the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

The FDA has a fast track designation program that

is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria.

Specifically, new drugs

are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate

the potential to address unmet medical needs for the disease or condition.

With regard to a fast track product, the FDA may consider for

review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the

submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and

the sponsor pays any required user fees upon submission of the first section of the NDA.

Any product submitted to the FDA for approval, including

a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review,

such as priority review and accelerated approval.

A product is eligible for priority review if it is

intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to currently

marketed products.

The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for

priority review in an effort to facilitate the review.

The FDA endeavors to review applications with priority review designations within

six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA review goals.

In addition, a product may be eligible for accelerated

Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination

that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint

that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible

morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability

or lack of alternative treatments.

As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval

perform adequate and well-controlled post-marketing clinical trials.

Drugs receiving accelerated approval may be subject to expedited

withdrawal procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted

clinical benefit.

In addition, the FDA currently requires as a condition for accelerated approval, pre-approval of promotional materials,

which could adversely impact the timing of the commercial launch of the product.

The Food and Drug Administration Safety and Innovation

Act (“FDASIA”) established a category of drugs referred to as “breakthrough therapies” that may be eligible to

receive breakthrough therapy designation.

A sponsor may seek FDA designation of a compound as a “breakthrough therapy” if

the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition

and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or

more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.

The designation includes

all of the fast track program features, as well as more intensive FDA interaction and guidance.

The breakthrough therapy designation is

a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria

If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug.

Fast track designation, priority review and breakthrough

therapy designation do not change the standards for approval but may expedite the development or approval process.

However, even if a

product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification

or decide that the time period for FDA review or approval will not be shortened.

Orphan drug designation

Under the Orphan Drug Act, the FDA may grant

orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer

than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no

reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease

or condition will be recovered from sales of the product.

Under the Orphan Drug Act, the FDA may grant orphan

designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals

in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the

cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from

sales of the product.

Orphan designation must be requested before an NDA is submitted.

the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are publicly disclosed by

Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

After the FDA grants orphan designation, the identity

of the therapeutic agent and its potential orphan use are publicly disclosed by the FDA.

Orphan designation does not convey any advantage

in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently

receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan

product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication

for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity

or inability to manufacture the product in sufficient quantities.

The designation of such drug also entitles a party to financial

incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.

competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain

approval for the same product but for a different indication for which the orphan product has exclusivity.

Orphan exclusivity also

could block the approval of one of our compounds for seven years if our compound is determined to be contained within the competitor’s

product for the same indication or disease, or if a competitor obtains approval of the same drug as defined by the FDA.

if an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled

to orphan exclusivity.

Abbreviated New Drug Applications, 505(b)(2)

Applications, and Marketing exclusivity

In seeking approval for a drug through an NDA,

applicants are required to list with the FDA each patent with claims that cover the applicant’s drug or an approved method

of use of the drug.

Upon approval of a drug, each of the patents listed in the application for the drug is then published in the

FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book.” Drugs

listed in the Orange Book can, in turn, be cited by competitors in support of approval of an Abbreviated New Drug Application,

or ANDA, or a 505(b)(2) application.

In this case, the original NDA (the so-called pioneer drug) is known as the

“listed” drug or “reference-listed” drug.

An ANDA provides for marketing of a drug that has the same active

ingredient and the same strength, route of administration and dosage form as the listed drug and has been shown through testing

to be bioequivalent to the listed drug or receives a waiver from bioequivalence testing.

ANDA applicants are generally not required

to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug, other than the

requirement for bioequivalence testing.

Drugs approved in this way are considered therapeutically equivalent, and are commonly

referred to as “generic equivalents” to the listed drug.

These drugs then generally can be substituted by pharmacists

under prescriptions written for the original listed drug.

A 505(b)(2) application is a type of NDA that

relies, in part, upon data the applicant does not own and to which it does not have a right of reference.

Such applications often

are submitted for changes to previously approved drug products, and rely on the FDA’s prior findings of safety and effectiveness

for a third party’s NDA to abbreviate the showings the sponsor of the 505(b)(2) application must make to establish that its

product is safe and effective.

The ANDA or 505(b)(2) applicant is required

to certify to FDA concerning any patents listed for the referenced approved drug in FDA’s Orange Book.

Specifically, for

each listed patent, the applicant must certify that:

receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product

exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven

years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability

to manufacture the product in sufficient quantities.

The designation of such drug also entitles a party to financial incentives such as

opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.

However, competitors may receive approval

of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for

a different indication for which the orphan product has exclusivity.

Orphan exclusivity also could block the approval of one of our compounds

for seven years if our compound is determined to be contained within the competitor’s product for the same indication or disease,

or if a competitor obtains approval of the same drug as defined by the FDA.

In addition, if an orphan designated product receives marketing

approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.

Abbreviated New Drug Applications, 505(b)(2) Applications,

and Marketing exclusivity

In seeking approval for a drug through an NDA, applicants

are required to list with the FDA each patent with claims that cover the applicant’s drug or an approved method of use of the drug.

Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA’s Approved Drug

Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book.” Drugs listed in the Orange Book can,

in turn, be cited by competitors in support of approval of an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) application.

In this case, the original NDA (the so-called pioneer drug) is known as the “listed” drug or “reference-listed”

An ANDA provides for marketing of a drug that has the same active ingredient and the same strength, route of administration and

dosage form as the listed drug and has been shown through testing to be bioequivalent to the listed drug or receives a waiver from bioequivalence

ANDA applicants are generally not required to conduct or submit results of preclinical or clinical tests to prove the safety

or effectiveness of their drug, other than the requirement for bioequivalence testing.

Drugs approved in this way are considered therapeutically

equivalent, and are commonly referred to as “generic equivalents” to the listed drug.

These drugs then generally can be substituted

by pharmacists under prescriptions written for the original listed drug.

A 505(b)(2) application is a type of NDA that relies,

in part, upon data the applicant does not own and to which it does not have a right of reference.

Such applications often are submitted

for changes to previously approved drug products, and rely on the FDA’s prior findings of safety and effectiveness for a third party’s

NDA to abbreviate the showings the sponsor of the 505(b)(2) application must make to establish that its product is safe and effective.

The ANDA or 505(b)(2) applicant is required to

certify to the FDA concerning any patents listed for the referenced approved drug in FDA’s Orange Book.

Specifically, for each listed

patent, the applicant must certify that:

(1) the required patent information has not been filed;

listed patent has expired;

(3) the listed patent has not expired but will expire on a particular date and approval is sought

after patent expiration;

or (4) the listed patent is invalid, unenforceable or will not be infringed by the new drug.

A certification

that the new drug will not infringe the already approved drug’s listed patents or that such patents are invalid or unenforceable

is called a Paragraph IV certification.

If the ANDA or 505(b)(2) applicant does not include a Paragraph IV certification,

the ANDA or 505(b)(2) application will not be approved until all of the listed patents claiming the referenced drug have expired,

except for any listed patents that only apply to uses of the drug not being sought by the ANDA or 505(b)(2) applicant.

If the ANDA or 505(b)(2) applicant has

made a Paragraph IV certification, the applicant must also send notice of a Paragraph IV Notice Letter to the NDA and patent holders

once the ANDA or 505(b)(2) application has been accepted for filing by FDA.

The NDA and patent holders may then initiate a

patent infringement lawsuit in response to the notice of the Paragraph IV Notice Letter.

The filing of a patent infringement lawsuit

within 45 days of the receipt of notice of a Paragraph IV Notice Letter automatically prevents FDA from approving the ANDA

until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, modification by a court or a decision

in the infringement case that is favorable to the ANDA or 505(b)(2) applicant.

As discussed below, the ANDA or 505(b)(2) application

also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference-listed

drug has expired.

Market exclusivity provisions under the FDCA

can delay the submission or approval of certain marketing applications.

The FDCA provides a five-year period of non-patent marketing

exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity.

new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule

or ion responsible for the action of the drug substance.

During the exclusivity period, the FDA may not approve or even accept

for review an abbreviated new drug application (“ANDA”), or an NDA submitted under Section 505(b)(2) (a “505(b)(2)

NDA”), submitted by another company for another drug containing the same active moiety, regardless of whether the drug is

intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or

have a legal right of reference to all the data required for approval.

However, an application may be submitted after four years

if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator

The FDCA alternatively provides three years

of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability

studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,

for example new indications, dosages or strengths of an existing drug.

This three-year exclusivity covers only the modification

for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving

ANDAs or 505(b)(2) NDAs for drugs containing the active ingredient for the original indication or condition of use.

Five-year and

three-year exclusivity will not delay the submission or approval of a full NDA.

However, an applicant submitting a full NDA would

be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical

trials necessary to demonstrate safety and effectiveness.

(2) the listed patent has expired;

(3) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration;

listed patent is invalid, unenforceable or will not be infringed by the new drug.

A certification that the new drug will not infringe

the already approved drug’s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification.

If the ANDA or 505(b)(2) applicant does not include a Paragraph IV certification, the ANDA or 505(b)(2) application will not

be approved until all of the listed patents claiming the referenced drug have expired, except for any listed patents that only apply to

uses of the drug not being sought by the ANDA or 505(b)(2) applicant.

If the ANDA or 505(b)(2) applicant has made a

Paragraph IV certification, the applicant must also send notice of a Paragraph IV Notice Letter to the NDA and patent holders once the

ANDA or 505(b)(2) application has been accepted for filing by the FDA.

The NDA and patent holders may then initiate a patent infringement

lawsuit in response to the notice of the Paragraph IV Notice Letter.

The filing of a patent infringement lawsuit within 45 days of

the receipt of notice of a Paragraph IV Notice Letter automatically prevents the FDA from approving the ANDA until the earlier of 30 months,

expiration of the patent, settlement of the lawsuit, modification by a court or a decision in the infringement case that is favorable

to the ANDA or 505(b)(2) applicant.

As discussed below, the ANDA or 505(b)(2) application also will not be approved until any

applicable non-patent exclusivity listed in the Orange Book for the reference-listed drug has expired.

Market exclusivity provisions under the FDCA can delay

the submission or approval of certain marketing applications.

The FDCA provides a five-year period of non-patent marketing exclusivity

within the United States to the first applicant to obtain approval of an NDA for a new chemical entity.

A drug is a new chemical entity

if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible

for the action of the drug substance.

During the exclusivity period, the FDA may not approve or even accept for review an abbreviated

new drug application (“ANDA”), or an NDA submitted under Section 505(b)(2) (a “505(b)(2) NDA”), submitted by another

company for another drug containing the same active moiety, regardless of whether the drug is intended for the same indication as the

original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data

required for approval.

However, an application may be submitted after four years if it contains a certification of patent invalidity or

non-infringement to one of the patents listed with the FDA by the innovator NDA holder.

The FDCA alternatively provides three years of marketing

exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were

conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, as, for example, new

indications, dosages or strengths of an existing drug.

This three-year exclusivity covers only the modification for which the drug received

approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs

containing the active ingredient for the original indication or condition of use.

Five-year and three-year exclusivity will not delay

the submission or approval of a full NDA.

However, an applicant submitting a full NDA would be required to conduct or obtain a right of

reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing

exclusivity available in the United States.

Pediatric exclusivity provides for an additional six months of marketing exclusivity

attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from

The issuance of a written request does not require the sponsor to undertake the described clinical trials.

orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.

Pediatric exclusivity provides for an additional six months of marketing exclusivity attached

to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA.

issuance of a written request does not require the sponsor to undertake the described clinical trials.

In addition, orphan drug exclusivity,

as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.

United States Patent Term Restoration

2 unchanged sentences

under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments.

The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during

the FDA regulatory review process for a drug that has not been previously approved for commercial marketing.

Patent-term restoration,

however, cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date and only

those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended.

The patent-term

restoration period is generally one-half the time between the effective date of an IND and the submission date of an

NDA plus the time between the submission date of an NDA and the approval of that application, except that the review period is

reduced by any time during which the applicant failed to exercise due diligence.

Only one patent applicable to an approved drug

is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.

Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension

or restoration.

In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent

life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in

the filing of the relevant NDA.

The Hatch-Waxman

Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review

process for a drug that has not been previously approved for commercial marketing.

Patent-term restoration, however, cannot extend the

remaining term of a patent beyond a total of 14 years from the product’s approval date and only those claims covering such approved

drug product, a method for using it or a method for manufacturing it may be extended.

The patent-term restoration period is generally one-half the

time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the

approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence.

Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior

to the expiration of the patent.

Patent and Trademark Office, in consultation with the FDA, reviews and approves the application

for any patent term extension or restoration.

In the future, we may apply for restoration of patent term for our currently owned or licensed

patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors

involved in the filing of the relevant NDA.

Foreign Sales

Sales outside the United States of potential

drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing

The requirements vary widely from country to country, but typically the registration and approval process takes several

years and requires significant resources.

In most cases, if the FDA has not approved a potential drug compound for sale in the

United States, the potential drug compound may be exported for sale outside of the United States, only if it has been approved

in any one of the following:

the European Union or a country in the European Economic Area (the countries in the European Union

and the European Free Trade Association) if the drug or device is marketed in that country or the drug or device is authorized

for general marketing in the European Economic Area, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.

Sales outside the United States of potential drug

compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing for drugs.

The requirements vary widely from country to country, but typically the registration and approval process takes several years and requires

significant resources.

In most cases, if the FDA has not approved a potential drug compound for sale in the United States, the potential

drug compound may be exported for sale outside of the United States, only if it has been approved in any one of the following:

Union or a country in the European Economic Area (the countries in the European Union and the European Free Trade Association) if the

drug or device is marketed in that country or the drug or device is authorized for general marketing in the European Economic Area, Canada,

Australia, New Zealand, Japan, Israel, Switzerland and South Africa.

There are specific FDA regulations that govern this process.

2 unchanged sentences

and reimbursement status of any compound for which we may seek regulatory approval.

Sales in the United States will depend in part

on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health

programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private

health insurers.

Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge,

reduction or denial by payors.

The process for determining whether a payor

will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will

pay for the product.

A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate

will be available.

Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement.

payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies,

but also have their own methods and approval processes.

Therefore, coverage and reimbursement for products can differ significantly

from payor to payor.

If coverage and adequate reimbursement are not available, or are available only at limited levels, successful

commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.

Third-party payors are increasingly challenging

the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety

and efficacy.

In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to

conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be

in addition to the costs expended to obtain regulatory approvals.

Third-party payors may not consider our compounds to be medically

necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage

may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return

on our investment in drug development.

Additionally, we or our collaborators may develop companion diagnostic

tests for use with our product candidates.

Companion diagnostic tests require coverage and reimbursement separate and apart from

the coverage and reimbursement for their companion pharmaceutical or biological products.

Similar challenges to obtaining coverage

and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.

Sales in the United States will depend in part on

the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such

as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers.

Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject to challenge, reduction or denial

The process for determining whether a payor will provide

coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.

A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available.

Additionally,

in the United States there is no uniform policy among payors for coverage or reimbursement.

Third-party payors often rely upon Medicare

coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and

approval processes.

Therefore, coverage and reimbursement for products can differ significantly from payor to payor.

If coverage and adequate

reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory

financial return on, any product we develop may not be possible.

Third-party payors are increasingly challenging the

price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.

In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies

in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended

to obtain regulatory approvals.

Third-party payors may not consider our compounds to be medically necessary or cost-effective compared

to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost

or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.

Additionally,

we or our collaborators may develop companion diagnostic tests for use with our product candidates.

Companion diagnostic tests require

coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products.

Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion

Fraud and Abuse Laws

1 unchanged sentence

restrict business practices in the biopharmaceutical industry.

In the biopharmaceutical industry, there are a number of federal

and state health care regulatory requirements that apply to entities, including, but not limited to, the federal and state fraud

and abuse laws.

These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims act law, criminal

false statement law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative laws.

laws, regulations, and guidance continuously evolve and are thereby subject to constant change.

In the biopharmaceutical industry, there are a number of federal and state

health care regulatory requirements that apply to entities, including, but not limited to, the federal and state fraud and abuse laws.

These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims act law, criminal false statement

law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative laws.

Health care laws, regulations, and

guidance continuously evolve and are thereby subject to constant change.

The Federal Anti-Kickback Statute, 42 U.S.C.

§ 1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of

remuneration, whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the referral

of an individual for the:

or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid or other federal

healthcare programs;

lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable

in whole or in part under Medicare, Medicaid or other federal healthcare programs.

There are a number of narrow safe harbors to

the Federal Anti-Kickback Statute.

Such safe harbors permit certain payments and business practices that, although they would otherwise

potentially implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements

of the specific applicable safe harbor are met.

Actual knowledge of the statute or specific intent to violate it is not required

in order for a person or entity to have committed a violation.

The Federal Anti-Kickback Statute applies to

certain arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts

and other financial incentives offered in connection with the sales of our products.

Regulatory authorities may determine that

certain marketing, pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws.

Noncompliance

with the Federal Anti-Kickback Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability

to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid or other federal healthcare programs.

In addition, non-compliance can result in the need to curtail and/or restructure operations.

Any penalties, damages, fines, exclusions,

curtailment or restructuring of operations could adversely affect the ability to operate a business, financial condition, and results

of operations.

A violation of the Federal Anti-Kickback Statute can serve as a false or fraudulent claim for purposes of the civil

False Claims Act and the civil monetary penalties statute.

The federal Health Insurance Portability and

Accountability Act of 1996 (“HIPAA”) among other things, enacted numerous provisions that prohibit knowingly and willfully

executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false

or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of,

any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation

of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact

or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare

benefits, items or services relating to healthcare matters.

1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration,

whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the referral of an individual for

furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs;

purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs.

There are a number of narrow safe harbors to the Federal

Anti-Kickback Statute.

Such safe harbors permit certain payments and business practices that, although they would otherwise potentially

implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements of the specific applicable

safe harbor are met.

Actual knowledge of the statute or specific intent to violate it is not required in order for a person or entity

to have committed a violation.

The Federal Anti-Kickback Statute applies to certain

arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts and other

financial incentives offered in connection with the sales of our products.

Regulatory authorities may determine that certain marketing,

pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws.

Noncompliance with the Federal Anti-Kickback

Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability to operate in certain jurisdictions,

and exclusion from participation in Medicare, Medicaid or other federal healthcare programs.

In addition, non-compliance can result in

the need to curtail and/or restructure operations.

Any penalties, damages, fines, exclusions, curtailment or restructuring of operations

could adversely affect the ability to operate a business, financial condition, and results of operations.

A violation of the Federal Anti-Kickback

Statute can serve as a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute.

The federal Health Insurance Portability and Accountability

Act of 1996 (“HIPAA”) among other things, enacted numerous provisions that prohibit knowingly and willfully executing, or

attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses,

representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program,

regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly

and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious

or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare

These provisions include 18 U.S.C.

§§ 286, 287, 669, 1035,

§§ 286, 287, 669, 1035, 1347, and 1518, all as described further below.

The Ethics in Patient Referrals Act, commonly

known as the “Stark Law,” 42 U.S.C.

§ 1395nn, prohibits a physician from making referrals for certain “designated

health services” payable by Medicare to an entity in which the physician or an immediate family member of such physician

has an ownership or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory

exception applies.

The Ethics in Patient Referrals Act, commonly known

as the “Stark Law,” 42 U.S.C.

§ 1395nn, prohibits a physician from making referrals for certain “designated health

services” payable by Medicare to an entity in which the physician or an immediate family member of such physician has an ownership

or investment interest or with which the physician has entered into a compensation arrangement, unless a statutory exception applies.

There are a number of exceptions to the Stark Law.

Such exceptions permit certain payments and arrangements

that, although they would otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements

of the specific exceptions are met.

Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements

received under a noncompliance arrangement, civil penalties, damages and exclusion from Medicare or other governmental programs.

These requirements are highly technical and there can be no guarantee that regulatory authorities will not determine or assert

that arrangements are in violation of the Stark Law and do not otherwise meet applicable Stark Law exceptions.

Such exceptions permit certain payments and arrangements that, although they would

otherwise potentially implicate the Stark Law, are not treated as a violation under the same if the requirements of the specific exceptions

Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliance arrangement,

civil penalties, damages and exclusion from Medicare or other governmental programs.

These requirements are highly technical and there

can be no guarantee that regulatory authorities will not determine or assert that arrangements are in violation of the Stark Law and do

not otherwise meet applicable Stark Law exceptions.

The federal false statements statute, 42 U.S.C.

§ 1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any materially

false statement in connection with the delivery of health care benefits, items, or services.

1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any materially false statement

in connection with the delivery of health care benefits, items, or services.

Similarly, 18 U.S.C.

§ 1035 prohibits

a person or entity, in any matter involving a health care benefit program, from knowingly or willfully falsifying, concealing,

or covering up by any trick, scheme, or device a material fact;

making any materially false, fictitious, or fraudulent statements

or representations;

or making or using any materially false writing or document knowing the same to contain any materially false,

fictitious, or fraudulent statement or entry.

In addition to criminal penalties, violation of these statutes may result in collateral

administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.

§ 669 prohibits knowingly and

willfully embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the rightful

owner, or intentionally misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets of a health

care benefit program.

In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions,

including exclusion from participation in Medicare, Medicaid and other federal health care programs.

The criminal health care fraud statute, 18

§ 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme

or artifice to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations,

or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, in connection

with the delivery of or payment for health care benefits, items, or services.

In addition to criminal penalties, violation of this

statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other

federal health care programs.

A person or entity need not have actual knowledge of this law or specific intent to commit a violation

§ 1518 establishes criminal

liability for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication

of information or records relating to a violation of a Federal health care offense to a criminal investigator.

In addition to criminal

penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation

§ 1035 prohibits a person or entity,

in any matter involving a health care benefit program, from knowingly or willfully falsifying, concealing, or covering up by any trick,

scheme, or device a material fact;

making any materially false, fictitious, or fraudulent statements or representations;

using any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or

In addition to criminal penalties, violation of these statutes may result in collateral administrative sanctions, including exclusion

from participation in Medicare, Medicaid and other federal health care programs.

§ 669 prohibits knowingly and willfully

embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the rightful owner, or intentionally

misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets of a health care benefit program.

to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation

in Medicare, Medicaid and other federal health care programs.

The criminal health care fraud statute, 18 U.S.C.

§ 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme or artifice

to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations, or promises, any

of the money or property owned by, or under the custody or control of, any health care benefit program, in connection with the delivery

of or payment for health care benefits, items, or services.

In addition to criminal penalties, violation of this statute may result in

collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.

A person or entity need not have actual knowledge of this law or specific intent to commit a violation of this law.

§ 1518 establishes criminal liability

for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or agency thereof,

by obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim.

In addition to criminal

penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation

in Medicare, Medicaid and other federal health care programs.

for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication of information

or records relating to a violation of a Federal health care offense to a criminal investigator.

In addition to criminal penalties, violation

of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other

federal health care programs.

§ 286 establishes criminal liability

for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including any

department or agency thereof.

In addition to criminal penalties, violation of this statute may result in collateral administrative

sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.

for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or agency thereof, by

obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim.

In addition to criminal penalties,

violation of this statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid

and other federal health care programs.

§ 287 establishes criminal liability

for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including any department

or agency thereof.

In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions, including

exclusion from participation in Medicare, Medicaid and other federal health care programs.

The Federal False Claims Act, 31 U.S.C.

3729, et seq., provides, in part, that the federal government—or a private party on behalf of the government—may bring

a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim for

payment, or who has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation

to pay money to the federal government or who has knowingly retained an overpayment.

Knowledge under the Federal False Claims Act

means actual knowledge, deliberate indifference, or reckless disregard.

In addition, amendments in 1986 to the Federal False Claims

Act have made it easier for private parties to bring whistleblower lawsuits against companies.

et seq., provides, in part, that the federal government—or a private party on behalf of the government—may bring a lawsuit

against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim for payment, or who

has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation to pay money to the

federal government or who has knowingly retained an overpayment.

Knowledge under the Federal False Claims Act means actual knowledge,

deliberate indifference, or reckless disregard.

In addition, amendments in 1986 to the Federal False Claims Act have made it easier for

private parties to bring whistleblower lawsuits against companies.

The civil monetary penalties law, 42 U.S.C.

§ 1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who presents

or causes to be presented claims to a Federal health care program that the person knows or should know is for an item or services

that was not provided as claimed or is false or fraudulent, or the person has made a false statement or used a false record to

get a claim paid.

The federal government may also seek civil monetary penalties for a wide variety of other conduct, including

offering remuneration to influence a Medicare or Medicaid beneficiary’s selection of providers and violations of the Federal

Anti-Kickback Statute.

Violations of the Federal False Claims Act

and/or the Civil Monetary Penalties Law can result in penalties ranging from $12,537 to $25,076 for each false claim violation

of the Federal False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up

to three times the amount of damages that the federal government sustained.

In addition, the federal government may also seek exclusion

from participation in all federal health care programs.

1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who presents or causes to

be presented claims to a Federal health care program that the person knows or should know is for an item or services that was not provided

as claimed or is false or fraudulent, or the person has made a false statement or used a false record to get a claim paid.

government may also seek civil monetary penalties for a wide variety of other conduct, including offering remuneration to influence a

Medicare or Medicaid beneficiary’s selection of providers and violations of the Federal Anti-Kickback Statute.

Violations of the Federal False Claims Act and/or

the Civil Monetary Penalties Law can result in penalties ranging from $12,537 to $25,076 for each false claim violation of the Federal

False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up to three times the amount

of damages that the federal government sustained.

In addition, the federal government may also seek exclusion from participation in all

federal health care programs.

Section 1320a-7 provides that individuals

3 unchanged sentences

under a federal or state health care program, and a conviction related to health care fraud.

The grounds for permissive exclusion

include, but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions related to

obstruction of an investigation or audit, and/or failure to disclose certain required information.

Exclusion from federal health

care programs—whether mandatory or permissive—may mean that our customers may not be able to get reimbursed by federal

and/or state health care programs for use or dispensing of our products.

The grounds for permissive exclusion include,

but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions related to obstruction of an

investigation or audit, and/or failure to disclose certain required information.

Exclusion from federal health care programs—whether

mandatory or permissive—may mean that our customers may not be able to get reimbursed by federal and/or state health care programs

for use or dispensing of our products.

State Fraud and Abuse Provisions

Many states have also adopted some form of

anti-kickback and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions that

apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs.

A determination

of liability under such laws could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate

in these jurisdictions.

Corporate liability can be present as a result

of the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates, even

if they were not explicitly authorized.

There can be no assurance that all employees, representatives, contractors, collaborators,

agents, subsidiaries or affiliates will comply with the foregoing laws at all times.

Violation of the aforementioned and other

laws could result in whistleblower complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting,

other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions

or other administrative remedies, suspension and/or debarment from contracting with certain governments or other persons, the loss

of privileges, reputational harm, contract damages, adverse media coverage and other collateral consequences.

In addition, corporate

directors, officers, employees, and other representatives who engage in violations of these and other laws may face imprisonment,

fines, and penalties.

If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if a

company does not prevail in any possible civil or criminal litigation, business, financial condition, and results of operations

could be materially harmed.

In addition, responding to any action will likely result in a materially significant diversion of management’s

attention and resources and significant defense costs and other professional fees.

Enforcement actions and sanctions could further

harm business, financial condition, and results of operations.

Any of the consequences contained in this paragraph and section

could adversely affect the ability to operate the business, financial condition, and the results of operations.

The Sunshine Act requires manufacturers of

products reimbursed by Medicare, Medicaid or the Children’s Health Insurance Program (“CHIP”) to collect and

annually report detailed data to the Centers for Medicare and Medicaid Services (“CMS”) regarding payments or other

transfers of value to physicians, certain other health care providers (such as physicians assistants

and nurse practitioners), and teaching hospitals (“covered recipients”), as well as any ownership or investment

interest held by physicians and their immediate family members.

The reporting data must be accompanied by an attestation as to

the accuracy of the data and failure to timely and accurately submit required information may result in civil monetary penalties.

Many states have also adopted some form of anti-kickback

and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions that apply regardless of

payer, in addition to items and services reimbursed under Medicaid and other state programs.

A determination of liability under such laws

could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate in these jurisdictions.

Corporate liability can be present as a result of

the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates, even if they were

not explicitly authorized.

There can be no assurance that all employees, representatives, contractors, collaborators, agents, subsidiaries

or affiliates will comply with the foregoing laws at all times.

Violation of the aforementioned and other laws could result in whistleblower

complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting, other enforcement actions, disgorgement

of profits, significant fines, damages, other civil and criminal penalties or injunctions or other administrative remedies, suspension

and/or debarment from contracting with certain governments or other persons, the loss of privileges, reputational harm, contract damages,

adverse media coverage and other collateral consequences.

In addition, corporate directors, officers, employees, and other representatives

who engage in violations of these and other laws may face imprisonment, fines, and penalties.

If any subpoenas or investigations are launched,

or governmental or other sanctions are imposed, or if a company does not prevail in any possible civil or criminal litigation, business,

financial condition, and results of operations could be materially harmed.

In addition, responding to any action will likely result in

a materially significant diversion of management’s attention and resources and significant defense costs and other professional

Enforcement actions and sanctions could further harm business, financial condition, and results of operations.

Any of the consequences

contained in this paragraph and section could adversely affect the ability to operate the business, financial condition, and the results

of operations.

The Sunshine Act requires manufacturers of products

reimbursed by Medicare, Medicaid or the Children’s Health Insurance Program (“CHIP”) to collect and annually report

detailed data to the Centers for Medicare and Medicaid Services (“CMS”) regarding payments or other transfers of value to

physicians, certain other health care providers (such as physicians assistants and nurse practitioners) and teaching hospitals (“covered

recipients”), as well as any ownership or investment interest held by physicians and their immediate family members.

The reporting

data must be accompanied by an attestation as to the accuracy of the data and failure to timely and accurately submit required information

may result in civil monetary penalties.

Health Insurance Portability and Accountability

1 unchanged sentence

described above, HIPAA, also created a new set of privacy and security requirements.

As amended by the Health Information Technology

for Economic and Clinical Health Act, and implementing regulations thereunder, HIPAA requires certain healthcare providers, health

plans and healthcare clearinghouses who conduct specified electronic healthcare transactions (“covered entities”),

as well as their independent contractors and agents who conduct certain activities involving protected health information on their

behalf (“business associates”) to comply with enumerated requirements relating to the privacy, security and transmission

of protected health information.

Failure to comply with HIPAA can result in corrective action, as well as civil fines and penalties

and government oversight.

Among other changes, HITECH made HIPAA security standards directly applicable to business associates,

increased the tiered civil and criminal fines and penalties that may be imposed against covered entities, business associates and

possibly other persons, and gave state attorneys general new authority to file actions to enforce HIPAA.

Further, the breach notification

rule implemented under HITECH requires covered entities to notify affected individuals, the U.S.

Department of Health and Human

Services Office of Civil Rights (“OCR”), the agency that enforces HIPAA, and for breaches affecting more than 500 individuals,

the media, of any breaches of unsecured protected health information.

HIPAA does not create a private right of action for individuals,

though individuals may submit complaints related to HIPAA to OCR.

Legislative Activities Aimed at Controlling

In the United States, there have been, and

continue to be proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency

to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare,

and reform government program reimbursement methodologies for drugs.

For example, in July 2021, the Biden administration released

an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription

In response to Biden’s executive order, on September 9, 2021, the U.S.

Department of Health and Human Services (“HHS”)

released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety

of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance

these principles.

In addition, the Inflation Reduction Act (“IRA”) passed on August 16, 2022.

The IRA, among other

things, (1) directs HHS to negotiate the price of certain highly-utilized single-source drugs and biologics covered under Medicare

and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation.

These provisions

will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges.

It is currently

unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.

Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within 90 days

on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for

Medicare and Medicaid beneficiaries.

As amended by the Health Information Technology for

Economic and Clinical Health Act, and implementing regulations thereunder, HIPAA requires certain healthcare providers, health plans and

healthcare clearinghouses who conduct specified electronic healthcare transactions (“covered entities”), as well as their

independent contractors and agents who conduct certain activities involving protected health information on their behalf (“business

associates”) to comply with enumerated requirements relating to the privacy, security and transmission of protected health information.

Failure to comply with HIPAA can result in corrective action, as well as civil fines and penalties and government oversight.

changes, HITECH made HIPAA security standards directly applicable to business associates, increased the tiered civil and criminal fines

and penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general

new authority to file actions to enforce HIPAA.

Further, the breach notification rule implemented under HITECH requires covered entities

to notify affected individuals, the U.S.

Department of Health and Human Services Office of Civil Rights (“OCR”), the agency

that enforces HIPAA, and for breaches affecting more than 500 individuals, the media, of any breaches of unsecured protected health information.

HIPAA does not create a private right of action for individuals, though individuals may submit complaints related to HIPAA to OCR.

Legislative Activities Aimed at Controlling Drug

In the United States, there have been, and continue

to be proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug

pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform

government program reimbursement methodologies for drugs.

For example, in July 2021, the Biden administration released an executive order,

“Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs.

In response to Biden’s

executive order, on September 9, 2021, the U.S.

Department of Health and Human Services (“HHS”) released a Comprehensive Plan

for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies

that Congress could pursue as well as potential administrative actions HHS can take to advance these principles.

the Inflation

Reduction Act (“IRA”) passed on August 16, 2022.

The IRA, among other things, (1) directs HHS to negotiate the price of certain

highly-utilized single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part

D to penalize price increases that outpace inflation.

These provisions will take effect progressively starting in fiscal year 2023, although

they may be subject to legal challenges.

It is currently unclear how the IRA will be implemented but is likely to have a significant impact

on the pharmaceutical industry.

Further, the Biden administration released an additional executive order on October 14, 2022, directing

HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models

for lowering drug costs for Medicare and Medicaid beneficiaries.

We expect that additional U.S.

federal healthcare reform measures will be adopted in the future,

any of which could limit the amounts that the U.S.

federal government will pay for healthcare products and services, which could

result in reduced demand for our product candidates or additional pricing pressures.

federal healthcare reform measures will

be adopted in the future, any of which could limit the amounts that the U.S.

federal government will pay for healthcare products and services,

which could result in reduced demand for our product candidates or additional pricing pressures.

Research and Development Expenses

Historically, a significant portion of our

operating expenses has related to research and development.

See our Consolidated Financial Statements contained elsewhere in this

Annual Report for costs and expenses related to research and development, and other financial information for fiscal years 2023,

2022 and 2021.

Historically, a significant portion of our operating

expenses related to research and development.

See our Consolidated Financial Statements contained elsewhere in this Annual Report for

costs and expenses related to research and development, and other financial information for fiscal years 2024 and 2023.

Scientific Advisors

We are advised by

scientists and physicians with experience relevant to our Company and our product candidates.

Our scientific advisors include

clinicians and scientists who are affiliated with a number of highly regarded medical institutions.

We currently have approximately forty full-time

We are advised by scientists and physicians with experience

relevant to our Company and our product candidates.

Our scientific advisors include clinicians and scientists who are affiliated with

a number of highly regarded medical institutions.

We currently have approximately forty-two full-time

employees, and we retain several independent contractors on a regular or as-needed basis.

We believe that we have good relations

with our employees.

We believe that we have good relations with

our employees.

Available Information

Our internet website address is www.anavex.com.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed

or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available there free of charge.

We include our website

address in this report only as an inactive textual reference and do not intend it to be an active link to our website.

of our website are not incorporated into this report.

Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished

pursuant to section 13(a) or 15(d) of the Exchange Act are available there free of charge.

We include our website address in this report

only as an inactive textual reference and do not intend it to be an active link to our website.

The contents of our website are not incorporated

into this report.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business